{"title": "Fatores clínicos e prognósticos no transtorno de ansiedade generalizada", "authors": ["Garcia, Rafael Ferreira", "Freire, Rafael Christophe da Rocha orient.", "Berger, William coorient.", "Universidade Federal do Rio de Janeiro. Instituto de Psiquiatria."], "abstract": "ste trabalho tem por objetivo identificar elementos clínicos e fisiológicos que sejam relacionados ao prognóstico e à resposta ao tratamento no transtorno de ansiedade generalizada (TAG). Buscamos também avaliar sua relação com outras facetas clínicas e correlatos fisiológicos, além de sua relação com potenciais elementos de confundimento. No estudo inicial, realizamos uma revisão sistemática de ensaios clínicos buscando preditores de resposta ao tratamento farmacológico no TAG. Em nossos resultados, neuroticismo, tratamento anterior, polimorfismos genéticos, e a ativação do cíngulo anterior e da amígdala, além de sintomas subclínicos de depressão, foram encontrados como potenciais preditores de resposta ao tratamento no TAG. Discutimos o papel da regulação emocional como elemento de intercessão de alguns preditores biológicos e psicológicos. No estudo subsequente avaliamos o papel da prevalência de emoções negativas na impulsividade de pacientes com TAG e controles saudáveis. Nossos resultados confirmaram nossa hipótese de que indivíduos com TAG relatam aumento da impulsividade em geral quando comparados a controles saudáveis, e que pacientes com TAG tendem a ser mais impulsivos na presença de emoções negativas, confirmando indiretamente a relação já demonstrada na literatura entre urgência negativa e sintomas de TAG. Discutimos também a interação dos transtornos de ansiedade com o diagnóstico de transtorno de déficit de atenção e hiperatividade. Por fim, no último estudo relatado, demonstramos que a variabilidade da frequência cardíaca é um potencial biomarcador de resposta ao tratamento por mindfulness, quando comparado com farmacoterapia.", "bibliography_pages": [120, 122], "keywords": ["Transtornos de ansiedade", "Frequência cardíaca", "Afeto", "Comportamento impulsivo", "Tratamento farmacológico"], "urls": ["http://objdig.ufrj.br/52/teses/889681.pdf", "http://lattes.cnpq.br/0044320768942997"], "pdf_url": "http://objdig.ufrj.br/52/teses/889681.pdf", "id": "889681", "sentences": ["iv RESUMO FATORES CLÍNICOS E PROGNÓSTICOS NO TRANSTORNO DE ANSIEDADE GENERALIZADA Este trabalho tem por objetivo identificar elementos clínicos e fisiológicos que sejam relacionados ao prognóstico e à resposta ao tratamento no transtorno de ansiedade generalizada (TAG). Buscamos também avaliar sua relação com outras facetas clínicas e correlatos fisiológicos, além de sua relação com potenciais elementos de confundimento. No estudo inicial, realizamos uma revisão sistemática de ensaios clínicos buscando preditores de resposta ao tratamento farmacológico no TAG. Em nossos resultados, neuroticismo, tratamento anterior, polimorfismos genéticos, e a ativação do cíngulo anterior e da amígdala, além de sintomas subclínicos de depressão, foram encontrados como potenciais preditores de resposta ao tratamento no TAG. Discutimos o papel da regulação emocional como elemento de intercessão de alguns preditores biológicos e psicológicos. No estudo subsequente avaliamos o papel da prevalência de emoções negativas na impulsividade de pacientes com TAG e controles saudáveis. Nossos resultados confirmaram nossa hipótese de que indivíduos com TAG relatam aumento da impulsividade em geral quando comparados a controles saudáveis, e que pacientes com TAG tendem a ser mais impulsivos na presença de emoções negativas, confirmando indiretamente a relação já demonstrada na literatura entre urgência negativa e sintomas de TAG. Discutimos também a interação dos transtornos de ansiedade com o diagnóstico de transtorno de déficit de atenção e hiperatividade. Por fim, no último estudo relatado, demonstramos que a variabilidade da frequência cardíaca é um potencial biomarcador de resposta ao tratamento por mindfulness, quando comparado com farmacoterapia.", "v ABSTRACT CLINICAL AND PROGNOSTIC FACTORS IN GENERALIZED ANXIETY DISORDER This study aims to identify clinical and physiological elements that are related to prognosis and treatment response in generalized anxiety disorder (GAD). We also sought to evaluate its relationship with other clinical facets and physiological correlates, as well as their relationship with potential confounders. In the initial study, we conducted a systematic review of clinical trials seeking predictors of response to pharmacological treatment in GAD. In our results, neuroticism, previous treatment, genetic polymorphisms, and anterior cingulate and amygdala activation, as well as subclinical symptoms of depression, were found as potential predictors of treatment response in GAD. We discuss the role of emotional regulation as an intercessory element of some biological and psychological predictors. In the subsequent study we evaluated the role of the prevalence of negative emotions on impulsivity in patients with GAD and healthy controls. Our results confirmed our hypothesis that individuals with GAD report increased overall impulsivity compared to healthy controls, and that patients with GAD tend to be more impulsive in the presence of negative emotions, indirectly confirming the relationship already shown in the literature between negative urgency and GAD symptoms. We also discuss the interaction of anxiety disorders with the diagnosis of attention deficit hyperactivity disorder. Finally, in the last study reported, we demonstrated that heart rate variability is a potential biomarker of response to mindfulness treatment when compared with pharmacotherapy.", "1 INTRODUÇÃO", "OBJETIVOS 10 1 INTRODUÇÃO 1", "1 APRESENTAÇÃO A mãe do autor conta como anedota familiar que em algum momento perto dos meus seis anos de idade eu a acordei num sábado pela manhã com a seguinte pergunta: “Mãe, o infinito é infinito mesmo, ou os cientistas que ainda não descobriram o fim?” Eu fiz várias perguntas desde então, que atrapalharam em maior ou menor grau o sono dos meus familiares", " Naturalmente, logo no início da minha vida acadêmica, durante a minha graduação na Faculdade Nacional de Medicina, a rotina nas enfermarias e nos ambulatórios me ofereceu uma nova pergunta, que parece óbvia à primeira vista: “Apesar do tratamento adequado por que alguns pacientes melhoram e outros não?” Mais que perguntas, meu interesse específico na melhora dos pacientes me fez abandonar a ideia de ser neurologista e decidir pela psiquiatria", " Em 2005 passei a acompanhar o ambulatório de transtorno obsessivo compulsivo orientado pelo professor Leonardo Fontenelle ainda na graduação, onde segui durante a residência, quando tive a oportunidade de estagiar no laboratório do professor David Mataix-cols no Institute of Psychiatry do King’s College em Londres", " Segui para meu mestrado em 2010, avaliando pacientes com lesões dos gânglios da base e sua interação com a psiquiatria, quando aprofundei meus estudos sobre correlatos dos sintomas psiquiátricos no cérebro", " Depois de um período trabalhando na subsecretaria de saúde mental com a administração da rede do município, a influência da Dra", " Marina Mochcovitch, fez meu interesse por transtornos de ansiedade novamente aparecer", " Especificamente o transtorno de ansiedade generalizada (TAG) parecia um diagnóstico menos estudado, com pacientes com características heterogêneas, e que parecia responder de forma relativamente imprevisível ao tratamento farmacológico", " OBJETIVOS 11 Influenciado por um trabalho publicado em colaboração com o professor Mataix-cols em 2014, sobre preditores de resposta ao tratamento no transtorno obsessivo compulsivo, iniciei então minha participação no Laboratório de Pânico e Respiração sob a orientação do Professor Rafael Freire, em 2015, onde colaboramos em um projeto conjunto, para estudar correlatos da resposta ao tratamento no TAG", " Iniciamos a captação de pacientes para um ambulatório específico, e coletamos os dados finalmente utilizados para desenvolver as pesquisas nesta tese", " 1", "2 INTRODUÇÃO O transtorno de ansiedade generalizada (TAG) é uma condição crônica, caracterizada pela presença de preocupação claramente excessiva e incontrolável sobre diversos eventos ou atividades rotineiras, associada à sensação de ansiedade subjetiva persistente, acompanhados por combinações variáveis de inquietação, cansaço, dificuldade de concentração, lapsos de memória, irritabilidade, tensão muscular e perturbação do sono (AMERICAN PSYCHIATRIC ASSOCIATION, 2013)", " Afeta cerca de 5% da população geral, ao longo da vida (KESSLER; KELLER; WITTCHEN, 2001), e está associado a piora da qualidade de vida e disfunção comparáveis ao transtorno depresivo maior (HOFFMAN; DUKES; WITTCHEN, 2008)", " O conceito de TAG surgiu no Diagnostic Statistical Manual 3rd edition (DSM-III) e, inicialmente, era considerado uma característica diagnóstica residual", " Foi no DSM–IV que o aperfeiçoamento na distinção entre TAG e ansiedade “normal” ou adaptativa foi mais bem caracterizada, assim como seu estabelecimento como categoria nosológica distinta (MOCHCOVITCH, 2015)", " O TAG é uma categoria diagnóstica que tem sua validade nosológica frequentemente questionada devido a suas sobreposições com sintomas de depressão e outros transtornos de ansiedade, ou pelo fato de ser apenas quantitativamente diferenciado do estado de normalidade", " A evolução dos critérios diagnósticos e o foco na presença de preocupações patológicas tornou OBJETIVOS 12 a distinção clínica mais evidente, e como demonstrado por estudos populacionais e clínicos, confirmando a viabilidade do TAG como um diagnóstico separado, confiavelmente isolável dos demais, e independentemente relacionado a sintomas e prejuízo em qualidade de vida (ANDREWS et al", ", 2010)", " O sintoma cardinal do TAG é a presença de preocupações diuturnas2 patológicas", " De fato, pacientes com TAG apresentam um maior número de assuntos ou áreas de preocupação em comparação com pacientes sofrendo de outros transtornos de ansiedade e controles não ansiosos, e gastam mais tempo do dia em torno de suas preocupações (BECKER et al", ", 1998)", " Os assuntos preocupantes mais comumente relatados são relacionados à família, relações próximas, trabalho, escola, finanças, saúde e violência, mas nenhum tema específico parece diferenciar as preocupações patológicas presentes no TAG das preocupações habituais em indivíduos não ansiosos (SANDERSON; BARLOW, 1990)", " Embora o conteúdo específico das preocupações não seja específico para o diagnóstico do TAG, a forma das preocupações, no entanto, parece ser em ao menos dois aspectos: (1) pacientes com TAG tendem a se preocupar mais com eventos remotos no tempo ou em probabilidade (por exemplo, um jovem recém-formado com a aposentadoria, ou a possibilidade de um filho saudável ter uma doença grave) (DUGAS et al", ", 1998), e (2) com problemas menos graves, em quando comparados com controles e indivíduos com outros transtornos de ansiedade (SANDERSON; BARLOW, 1990)", " De fato, a pergunta “Você se preocupa excessivamente 2 worrying", " OBJETIVOS 13 com problemas menores?” parece ser 94% específica para o diagnóstico do TAG (STEIN; HOLLANDER; ROTHBAUM, 2010)", " A experiência da preocupação também parece ser especificamente diferente em pacientes com TAG", " O controle sobre os pensamentos de preocupação, ou seja e a capacidade de inibir o fluxo de pensamentos e direcionar as faculdades mentais para uma tarefa alternativa parecem estar diminuídos em indivíduos com TAG (BECKER et al", ", 1998), bem como este grupo percebe mais frequentemente suas preocupações como “fora de controle” ", " Embora a percepção de dificuldade no controle das preocupações seja critério necessário para o diagnóstico do TAG pelo DSM-5, esta parece não ser um determinante diagnóstico", " Aparentemente o critério “A”, isto é, a percepção da preocupação como excessiva abarca a maior parte da variância, e menos de 0,3% dos diagnósticos seriam reclassificados caso este critério fosse excluído", " Clinicamente este fato pode ser traduzido na seguinte pergunta “É possível a preocupação ser excessiva, mas ainda assim controlável?”", " A resposta para esta pergunta parece ser “não” (ANDREWS et al", ", 2010)", " Sintomas de ansiedade inespecíficos são frequentemente associados aos sintomas cognitivos, e são mais prevalentes em pacientes com TAG em comparação com controles e pacientes com preocupações não patológicas", " Tensão muscular, inquietude e sensação de ter “os nervos à flor da pele” são fortemente sugestivas do diagnóstico, quando presentes cronicamente e associadas aos sintomas cognitivos", " Já os sintomas de fadigabilidade, irritabilidade, insônia e desatenção se sobrepõem significativamente com sintomas de depressão, portanto, embora frequentes, não são especialmente úteis para o diagnóstico (ANDREWS et al", ", 2010; STEIN; HOLLANDER; ROTHBAUM, 2010)", " OBJETIVOS 14 1", "2", "1 Correlatos Fisiológicos A fisiopatologia do TAG parece envolver dois sistemas neurais parcialmente superpostos: (1) o sistema de detecção de perigo, representado pela reatividade da amígdala e estruturas do circuito do medo (2) e o sistema de inibição e regulação emocional, representado pelo controle inibitório exercido pelo córtex pré-frontal dorsolateral na atividade da amígdala", " Pacientes com TAG parecem apresentar prejuízos no processo de regulação, emocional, que teria como reação compensatória um excesso de preocupações e ansiedade (MENNIN et al", ", 2005)", " Este prejuízo tem como correlato neurobiológico uma diminuição tanto na ativação, quanto na conectividade do córtex pré-frontal com a amígdala em tarefas de regulação emocional, apresentada por pacientes com TAG em relação a controles (MOCHCOVITCH et al", ", 2014)", " De fato, estudos utilizando imagem de ressonância magnética funcional (IRMf) utilizaram exposição a figuras emocionais para identificar correlatos neurais de regulação emocional como preditores de resposta ao tratamento no TAG", " Pacientes com maior atividade no giro do cíngulo durante a exposição, e menor atividade durante o período antecipatório aos estímulos emocionais negativos, apresentaram uma melhor resposta ao tratamento (MOCHCOVITCH et al", ", 2014)", " Apesar da ênfase nos relatos verbais de sintomas de ansiedade no TAG, os modelos patofisiológicos predominantes assumem que os sintomas referidos pelos pacientes devem evidenciar padrões correspondentes de ativação fisiológica, especialmente no balanço dos sistemas simpático e parassimpático do nervoso autonômico (THAYER et al", ", 2012)", " Uma das formas de monitorar o balanço relativo entre os sistemas simpático e parassimpático é a avaliação do seu efeito no ritmo cardíaco", " A atividade simpática afeta o ritmo cardíaco aumentando a frequência de disparo das células marca-passo no nodo sinoatrial, enquanto a atividade parassimpática diminui a frequência de disparo nas mesmas células", " No OBJETIVOS 15 entanto, a contribuição dos diferentes sistemas para o ritmo cardíaco ocorre por meio da modulação com frequências diferentes – a atividade simpática é relacionada com a potência em um intervalo de altas frequências em relação à atividade parassimpática", " Esta diferença permite estimar, após a decomposição dos componentes no domínio da frequência, índices de atividade simpática e parassimpática (ACHARYA et al", ", 2006)", " A diminuição do tônus vagal, indicada pela análise espectral da variabilidade da frequência cardíaca (VFC), é relacionada a ansiedade medida como traço ou estado, e à atividade no cíngulo anterior (THAYER et al", ", 2012)", " Embora esta medida psicofisiológica seja candidata a um marcador para TAG, relativamente poucos estudos avaliaram o papel da VFC no TAG, apresentando resultados contraditórios (CHANG et al", ", 2013; LANG; MCTEAGUE, 2009)", " A VFC também foi relacionada à percepção e reconhecimento de expressões faciais em voluntários saudáveis", " Especificamente, a maior intensidade do tônus vagal (maior VFC) foi positivamente correlacionada com uma maior habilidade de reconhecimento de expressões de medo (PARK et al", ", 2012)", " Em pacientes com transtorno de ansiedade social foi evidenciada diminuição da VFC (tônus vagal reduzido) durante a exibição de faces emocionais, indicando deficiência no controle emocional (GAEBLER et al", ", 2013)", " 1", "2", "2 Impulsividade A impulsividade é uma variável clínica que que influencia a patogênese e o curso dos transtornos mentais (MOELLER et al", ", 2001)", " Nos transtornos de humor, no transtorno de déficit de atenção e hiperatividade, em alguns transtornos de personalidade e, obviamente, nos transtornos de controle de impulso, a impulsividade apresenta um papel conhecido nas respectivas constelações sintomatológicas, porém, no caso do TAG, o papel da impulsividade OBJETIVOS 16 é muito pouco explorado, apesar de se conhecer uma relação positiva entre ansiedade e impulsividade (APTER et al", ", 1990)", " O papel das emoções negativas e da regulação emocional na gênese da impulsividade em pacientes com TAG foi sugerido previamente", " Em um estudo em uma população não clínica, pessoas com altos escores no na escala de sete itens de avaliação de ansiedade generalizada (GAD-7) apresentaram uma maior propensão a atos impulsivos relacionados a afeto negativo (urgência negativa), porém mais premeditação e menor impulsividade funcional (a habilidade de tomar ações rápidas quando necessário)(PAWLUK; KOERNER, 2013)", " Impulsividade em pacientes com TAG também foi relacionada a traços de personalidade, especificamente traços de busca de novidade, que foram preditivos de impulsividade globalmente, enquanto os de autodirecionamento (a capacidade de comandar e executar as próprias ações) foram protetores de impulsividade por não planejamento", " Nenhum estudo, no entanto, comparou essas relações entre indivíduos com TAG e controles, bem como as correlações com sintomas específicos de TAG (PIERÒ, 2010)", " Medidas de impulsividade parecem estar diretamente associadas a medidas de temperamento (CLONINGER; SVRAKIC; PRZYBECK, 1993), e regulação emocional", " Uma abordagem combinada destas dimensões pode ser muito útil na definição de endofenótipos que funcionem como marcadores diagnósticos e de resposta terapêutica (CONGDON; CANLI, 2008)", " 1", "2", "3 Tratamento e predição de resposta O tratamento farmacológico pode ser muito bem-sucedido na redução dos sintomas, e é capaz de e melhorar a função e qualidade de vida em pacientes que sofrem de TAG", " Taxas de resposta entre 49 e 69% podem ser obtidas com drogas tão diferentes como inibidores seletivos OBJETIVOS 17 de recaptação de serotonina (ISRS), antidepressivos tricíclicos, venlafaxina, hidroxizina, buspirona, benzodiazepínicos, antipsicóticos atípicos e pregabalina (Bereza et al", ", 2012)", " As diretrizes clínicas sugerem os ISRS sejam utilizados como primeira escolha no tratamento do TAG", " Estas medicações são adequadas ao uso prolongado e sua eficácia já foi demonstrada por diversos ensaios clínicos (BALDWIN; WALDMAN; ALLGULANDER, 2012)", " No entanto, os estudos mostram que pacientes com TAG apresentam frequência de resposta de 60 a 75% aos ISRS (BALDWIN, 2011)", " Assim, uma percentagem substancial dos pacientes não responde adequadamente ao tratamento, permanecendo sintomáticos ao final dos estudos", " Identificar fatores capazes de predizer a resposta às drogas de primeira linha para o TAG é um passo importante na busca da customização do tratamento, visto que pacientes potencialmente não responsivos à primeira linha de tratamento, poderiam ser submetidos a tratamentos distintos", " Dado o desconhecimento da relação entre elementos clínicos e os fatores preditivos de resposta ao tratamento, esta tese tem como objeto de estudo as potenciais variáveis relacionadas à predição de resposta no TAG", " Temos por objetivo identificar elementos clínicos e fisiológicos que sejam preditores de resposta ao tratamento, e avaliar sua relação com outras facetas do transtorno, além de sua relação com potenciais elementos de confundimento", " 1", "3 OBJETIVOS Este trabalho tem como objetivo geral identificar elementos clínicos e fisiológicos que associados ao curso do TAG, afetando decisões sobre o tratamento e prognóstico de pacientes com sintomas de ansiedade", " Buscamos especificamente: OBJETIVOS 18 1 - Realizar uma revisão sistemática da literatura sobre preditores de resposta ao tratamento no TAG, para melhor orientar as variáveis a serem estudadas", " 2 – Delinear a interrelação entre a impulsividade e os sintomas de ansiedade, e correlacionar com elementos clínicos e de regulação emocional", " 3 – Testar um correlato biológico de regulação emocional (variabilidade da frequência cardíaca) como preditora de resposta ao tratamento por duas modalidades distintas: farmacoterapia e uma intervenção baseada em mindfulness", "", "2 DESENVOLVIMENTO", "DESENVOLVIMENTO 20 2 DESENVOLVIMENTO 2", "1 ESTUDO 1 - PREDITORES DE RESPOSTA AO TRATAMENTO FARMACOLÓGICO NO TRANSTORNO DE ANSIEDADE GENERALIZADA: UMA REVISÃO SISTEMÁTICA Publicado em: Harvard review of psychiatry, v", " 25, n", " 2, p", " 65-79, 2017", " Predictors of pharmacotherapy response in generalized anxiety disorder: A systematic review Rafael Ferreira-Garcia, MD MS, Marina Mochcovitch, MD MS, Mariana Cabo, MD, Antonio E", " Nardi, MD PhD, Rafael Christophe da Rocha Freire, MD PhD Laboratório de Pânico e Respiração Instituto de Psiquiatria - Universidade Federal do Rio de Janeiro Running Head: PREDICTORS OF GAD DRUG RESPONSE Correspondence and reprints: Rafael Ferreira-Garcia Instituto de Psiquiatria - UFRJ Av", " Venceslau Brás, 71 – fundos", " Botafogo Rio de Janeiro –RJ CEP: 22290-140 Email: rfgarcia@ufrj", "br Conflicts of Interest and Source of Funding: RFG is an employee of the Federal University of Rio de Janeiro and had a research scholarship from CAPES", " Dr", " MM currently receives a research scholarship from CAPES", " MCC held a scientific initiation scholarship from UFRJ", " RCRF is an employee of the Federal University of Rio de Janeiro and received research scholarships from CNPq and CAPES", " AEN is employee of the Federal University of Rio de Janeiro", " He has been a consultant and received research grants from CNPq and FAPERJ", " The DESENVOLVIMENTO 21 authors report no conflicts of interest", " The authors alone are responsible for the content and writing of the article", " 2", "1", "1 Abstract Background: Pharmacotherapy for generalized anxiety disorder (GAD) may be effective in reducing symptoms in the majority of patients", " The study of moderators and predictors of treatment response may help clinicians both to select appropriate interventions to maximize the probability of response and to inform the general prognosis", " Methods: A systematic literature search of electronic databases, selected authors, and reference lists was used to identify articles that reported trials of drug monotherapy in GAD", " Data on predictors and moderators were extracted", " Quality of evidence was determined by the presence of a priori hypotheses, number of variables investigated, adequate quality of the measurement, and use of interaction-effects testing", " Results: From the 98 articles meeting inclusion criteria, 24 reported a total of 22 factors associated with treatment response", " The reported results were heterogeneous, ranging over sociodemographic, clinical, comorbidity, genetic, and functional-imaging studies", " Major depressive symptoms were found to moderate treatment outcome in favor of antidepressants versus benzodiazepines", " Neuroticism, previous treatment, genetic polymorphisms (including serotonin receptor gene 2A), and functional activation of the anterior cingulate cortex and amygdala were identified as potential predictors of treatment response", " Conclusions: Correlates of poor emotional regulation predicted poor treatment response, but subclinical depression was the only variable capable of informing treatment selection in this review", " Future research should focus on further exploring the value of depression as a moderator and on a narrower list of potential genetic, brain-imaging, and temperament predictors of response to pharmacotherapy in GAD", " DESENVOLVIMENTO DESENVOLVIMENTO 23 The major factors determining response to the first intervention in GAD are not yet known", " Inadequate treatment, which is thought to play a major role in compromising the effectiveness of drug interventions", " treatment, can result from of clinician-related factors, such as inadequate dosing regimens and lack of technical knowledge, or patient noncompliance", "6 But even in ideal circumstances, comorbid conditions, sociodemographic variables, genetic features, and personality styles are thought to interfere with prognosis", "7 Moreover, even with continuously evolving diagnostic criteria, different GAD patients may present somewhat different clinical features", " For instance, patients with mainly cognitive symptoms, as opposed to patients with mainly somatic symptoms, all meet criteria for the same disorder", " It is not clear whether these differences reflect distinct neurobiological correlates or whether they influence treatment response", " One way to address this uncertainty is to find predictor and moderator variables that identify subgroups of patients more likely to respond or that are better matched to particular interventions", " Predictors of treatment outcome are measurements that are taken before the treatment is started and that are associated with the results for all treatment interventions", " That is, they help identify who will respond, regardless of what intervention was used", " Effect moderators are variables that are associated with different outcomes for each subgroup in treatment", " In other words, it specifies for whom and under what conditions one treatment is more effective than others", "8 Predictors and moderators of treatment response have been identified in other mental disorders", " In obsessive-compulsive disorder, when functional magnetic resonance imaging shows lower pre-treatment activity in the orbitofrontal cortex and dorsolateral prefrontal cortex, or greater activity in the caudate and posterior cingulate cortex, a better treatment response can be predicted", "9,10 Clinical features such as early age of onset,11 hoarding symptoms,12,13 and delayed onset of treatment14 predict worse response", " In panic disorder, higher phobic avoidance DESENVOLVIMENTO 24 scores, longer duration of untreated illness, and comorbid personality disorder are associated with poor response to pharmacotherapy,15 whereas increased total cortical volume and metabolism, and predominant respiratory symptoms predict better outcome", "16,17 In major depressive disorder, studies have yielded data of immediate clinical relevance as a risk-stratification system for treatment resistance,18 and the presence of an inflammatory biomarker, C-reactive protein, may be useful as a moderator of treatment response to escitalopram or nortriptyline", "19 We evaluated the extent to which current evidence supports predictors of treatment response in GAD and the available evidence suggests any moderator effects of different drugs", " To organize the current literature and provide a framework for future confirmatory studies, we conducted a systematic review of published trials of the pharmacological treatment of GAD that reported predictors and moderators of treatment response", " DESENVOLVIMENTO 25 2", "1", "3 Methods Articles were identified primarily by a search of the MEDLINE database through PubMed and of the Cochrane Collaboration's Clinical Trials Register (CENTRAL)", " MEDLINE was searched using “generalized anxiety disorder” as a search term, filtered only for “trials,” and supplemented by searches for “generalized anxiety disorder” and “treatment response", "” CENTRAL was searched using the term “generalized anxiety disorder", "” The references of meta-analyses, reviews, key articles, and key authors were searched for additional studies", " Supplemental Text Box 1 lists the inclusion and exclusion criteria", " Main-effect data were extracted from studies that reported at least one test for a relationship between symptom outcome and a variable measured before treatment onset", " We allowed genetic variants to be measured after the study because their status would not be expected to change", " Thee variables were classified into three categories based on the characteristics of the analyses performed: 1", " Moderator analysis: variables that predict differential treatment effects between two or more interventions; 2", " Prediction analysis: variables that predict outcome without measuring differential effects of the interventions (including variables measured in single-arm studies); and 3", " Subgroup analysis: measurement of the effect of the intervention in different subgroups based on the baseline variables", " We classified the predictors found as follows: ¾ Sociodemographic: characteristics of the population studied (age, sex, ethnicity, education) ¾ Clinical: variables related to the symptoms and signs of GAD and its treatment (duration of illness, age of onset, previous treatments, specific symptoms) DESENVOLVIMENTO 26 ¾ Comorbidity: presence, severity, and other characteristics of comorbid psychiatric diagnoses or personality traits ¾ Biomarkers: laboratory measurements and genetic polymorphisms ¾ Neuroimaging: functional and structural brain studies Studies were also judged for the strength of the evidence presented", " Quality of predictors was judged based on the following factors: framework proposed for moderator analysis,8,20 presence of a priori hypotheses, less than five predictors investigated, adequate quality of the measurement, and testing for interaction effects", " Because we included trials with different designs, the presence of a controlling condition, randomization, and subject and observer blindness to treatment were used as measures of the strength of evidence", " Statistics were calculated using scripts in the R statistical environment", "21 The ideal confirmatory format of this review would involve of meta-analyses of interaction statistics of predictor and moderator effects in large, high-quality, randomized, controlled trials, as noted previously by other authors", "8,22 Because most studies included in this review did not meet quality requirements, and because their experimental designs were so varied, a qualitative systematic review of the evidence was employed", " DESENVOLVIMENTO 27 2", "1", "4 Results A total of 661 abstracts were screened, from which we selected 172 for full-text review, as detailed by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) diagram23 (Supplemental Figure 1)", " On full-text review, 73 articles were excluded: 37 for using either a combination of treatments or treatments that were not approved; 20 for including only previously treated or refractory patients; and 13 for unclear diagnostic criteria or multiple diagnoses", " Three review articles were also excluded", " From the 98 articles selected, 25 (25", "5%) mentioned at least one test measuring the relationship between baseline measures and treatment outcome", " Studies reporting measurements of predictor variables were significantly less likely to be double-blind, randomized, controlled trials (RCTs) than studies that did not (29% vs", " 77%; Fisher’s exact test, p < ", "001)", " From the studies reporting any test for predictors, we found seven double-blind RCTs, four pooled analyses of double-blind RCTs, 13 open-label trials, and 1 single-blind trial", " Studies that reported a test for predictors were more recent than ones not reporting any test (medians, 2006 vs", " 2002; Mann-Whitney U-test, p = ", "01), but they showed no significant differences in total sample sizes (n = 153 vs", " n = 205; Mann-Whitney U-test, p = 0", "69)", " Of the 24 studies found, 13 reported a priori hypotheses, and 11 were considered to conduct exploratory analyses", " As expected, articles testing a priori hypotheses were published later than exploratory ones (median, 2008 vs", " 2004; Mann-Whitney U-test, p = ", "01), and sample sizes were not different between the two groups (median, 110 vs", " 248; Mann-Whitney U-test, p = ", "29)", " Industry sponsorship was identified in 59", "2% of included studies", " Those studies tended to be less likely to test for predictors (19% vs", " 35%; Pearson’s Chi-squared test, p = ", "07), but this trend disappeared when study design was included in the model", " DESENVOLVIMENTO DESENVOLVIMENTO DESENVOLVIMENTO 30 Davidson, J", " R", ", et al", " (2004)17 0 Escitalopram 10mg, Placebo 0 + + + U + + + Steiner, M", ", et al", " (2005)21 0 Sertraline vs Placebo + + + + + + + + Stein, D", " J", ", Andersen, H", " F", ", and Goodman, W", " K", " (2005)20 0 Escitalopram vs Placebo + 0 + + + + + + Simon, N", " M", ", et al", " (2006)22 -1 Fluoxetine Worst prognosis only in late onset females + + + + + 0 0 0 Nicolini, H", ", et al", " (2009)24 0 + F Duloxetine 20, 60-120, Placebo Duloxetine 20mg did not separate from placebo in F + + + + + + + + Rickels, K", ", et al", " (2013)19 0 0 Venlafaxine + 0 + + 0 0 0 0 Etinicity Downing, R", " W", " and Rickels, K", " (1985)18 0 Diazepam 10mg 0 0 + + U 0 0 0 Nicolini, H", ", et al", " (2009)24 0 + Not caucasian 0 Duloxetine 20, 60-120, Placebo Only caucasians separated from placebo, no group effect + + + + + + + + Rickels, K", ", et al", " (2013)19 0 0 Venlafaxine + 0 + + 0 0 0 0 Education Downing, R", " W", " and Rickels, K", " (1985)18 0 Diazepam 10mg 0 0 + + U 0 0 0 Rickels, K", ", et al", " (2013)19 0 0 Venlafaxine + 0 + + 0 0 0 0 DESENVOLVIMENTO 31 2", "1", "4", "2 Clinical factors Previous treatment for GAD was tested as a potential predictor five times in four different studies (Table 2)", " Patients previously treated with antidepressants and, to a smaller extent, benzodiazepines had lower response rates to active treatment with venlafaxine versus placebo", "26 Additionally, in a subgroup with recent benzodiazepine use, active treatment with bupropion was not significantly different from placebo", "35 In a study of vortioxetine, patients with any history of previous treatment were not significantly different from placebo", "29 A single study found no relationship between previous treatment and treatment response", "34 A longer duration of untreated symptoms before the first treatment with an antidepressant, but not benzodiazepine, was associated with a worse response to treatment overall", "36 By contrast, age of onset and duration of illness alone did not have a significant association with treatment response in most of the studies reporting these variables", "24,26,27,33,36,37,40 Although baseline severity was either not associated or had a clinically irrelevant effect on treatment response in two separate studies,26,33 different GAD symptoms were found to have specific effects in one study of treatment response to venlafaxine versus placebo", " Pollack and colleagues26 tested the presence of GAD core symptoms and found that restlessness had a strong negative predictive effect on treatment, consistent at all timepoints for remission and response", " A negative effect was reported for fatigue, irritability, and muscle tension, albeit less consistently", " Somatic symptoms were associated with worse response in only one of two trials testing for this variable", "38,39 DESENVOLVIMENTO 32 TABELA 2 - CLINICAL PREDICTORS", " Variable Quality of Evidence Reference Predictor Subgroup = placebo Subgroup Moderator between drugs Intervention Obs A priori Hypothesis <5 Predictors accessed Measured before Study Adequate Quality of Measurement Test of interaction Controlled Trial Randomized Trial Blinded Trial Previous Treatment Rickels, K", ", et al", " (1993)29 0 Previous psychotropic treatment 0 Imipramine vs Trazodone vs Diazepam vs Placebo + + + + + + + + DeMartinis, N", ", et al", " (2000)28 1 Recent previous treatment with BDZ Buspirone vs Benzodiazepines vs Placebo Worse response to buspirone + + + + 0 + + + Pollack, M", " H", ", et al", " (2003)25 -1 Previous Non-BDZ treatment Venlafaxine vs placebo Venlafaxine worst at 8 and 24 weeks + 0 + + + + + + Pollack, M", " H", ", et al", " (2003) 25 -1 Previous BDZ treatment Venlafaxine vs placebo Small effect venlafaxine worst at 24 weeks + 0 + + + + + + Bidzan, L", ", et al", " (2012)26 1 Previously treated Vortioxetine vs Placebo + + + + 0 + + + Piero, A", " and Locati, E", " (2011)31 0 0 Escitalopram vs Duloxetine 0 + + + + 0 0 0 Duration of Illness / Chronicity Downing, R", " W", " and Rickels, K", " (1985)18 0 Diazepam 10mg 0 0 + + U 0 0 0 Rickels, K", ", et al", " (1993)29 0 0 Imipramine vs Trazodone vs + + + + + + + + DESENVOLVIMENTO 33 Diazepam vs Placebo Pollack, M", " H", ", et al", " (2003)23 1 Shorter duration of current episode Venlafaxine vs placebo Very small effect", " Clinically irrelevant", " pbo > venlafaxine + - + + + + + + Stein, D", " J", ", Andersen, H", " F", ", and Goodman, W", " K", " (2005)20 0 Escitalopram vs Placebo + 0 + + + + + + Altamura, A", " C", ", et al", " (2008)30 0 Duration of untreated illness before BDZ use <12 months 0 Venlafaxine vs SSRI + + + + + 0 + 0 Altamura, A", " C", ", et al", " (2008)30 -1 Duration of untreated illness before AD use <12 months 0 Venlafaxine vs SSRI + + + + + 0 + 0 Age of Onset Stein, D", " J", ", Andersen, H", " F", ", and Goodman, W", " K", " (2005)20 0 Escitalopram vs Placebo + 0 + + + + + + Simon, N", " M", ", et al", " (2006)22 -1 Fluoxetine Worst prognosis only in late onset females + + + + + 0 0 0 Rickels, K", ", et al", " (2013)19 0 Venlafaxine + 0 + + 0 0 0 0 Baseline Severity Pollack, M", " H", ", et al", " (2003)23 -1 Baseline HAM-A 0 Venlafaxine vs placebo Very small predictor effect", " Clinically irrelevant", " Pbo > venlafaxine at 8 weeks response + 0 + + + + + + Rickels, K", ", et al", " (2013)19 0 Baseline HAM-A Venlafaxine + 0 + + 0 0 0 0 DESENVOLVIMENTO 34 GAD Symptoms Wurthmann, C", ", Klieser, E", ", and Lehmann, E", " (1997)34 -1 Somatic symptoms Fluspirilene 0 + + 0 0 0 0 0 Pollack, M", " H", ", et al", " (2003)23 1 Restlessness Venlafaxine vs placebo Moderate effect, worst response and remission + 0 + + + + + + Pollack, M", " H", ", et al", " (2003)23 1 Easily fatigued Venlafaxine vs placebo Worst response at 24 weeks + 0 + + + + + + Pollack, M", " H", ", et al", " (2003) 23 1 Difficulty concentrating Venlafaxine vs placebo Pbo > venlafaxine at 8 weeks remission + 0 + + + + + + Pollack, M", " H", ", et al", " (2003) 23 -1 Irritability Venlafaxine vs placebo Worst response and remission at 24 weeks + 0 + + + + + + Pollack, M", " H", ", et al", " (2003) 23 -1 Muscle tension Venlafaxine vs placebo Less remission at 24 weeks, venlafaxine > pbo at 8 weeks response + 0 + + + + + + Pollack, M", " H", ", et al", " (2003) 23 1 Sleep disturbances Venlafaxine vs placebo Pbo > venlafaxine at 8, 24 weeks response, 24 weeks remission + 0 + + + + + + Meoni, P", ", Hackett, D", ", and Lader, M", " (2004)33 0 Somatic symptoms Venlafaxine vs placebo 0 + + + + + + + DESENVOLVIMENTO DESENVOLVIMENTO DESENVOLVIMENTO 37 TABELA 3 - COMORBIDITY / ASSOCIATED CONDITIONS PREDICTORS", " Variable Quality of Evidence Reference Predictor Subgroup = placebo Subgroup Moderator between drugs Intervention Obs A priori Hypothesis <5 Predictors accessed Measured before Study Adequate Quality of Measurement Test of interaction Controlled Trial Randomized Trial Blinded Trial Depression Downing, R", " W", " and Rickels, K", " (1985)18 0 Depression Diazepam 10mg 0 0 + 0 U 0 0 0 Rickels, K", ", et al", " (1993)29 0 Four DSM-III criteria for depression 1 Imipramine vs Trazodone vs Diazepam vs Placebo Worst response to Diazepam Excluded major depressive disorder", " + + + + + + + + Rickels, K", ", et al", " (1993)29 0 HAM-D, Raskin Imipramine vs Trazodone vs Diazepam vs Placebo + + + + + + + + Lader, M", " and Scotto, J", " C", " (1998)35 0 0 Mixed depression / anxiety Buspirone vs Hydroxyzine 0 + + 0 0 0 + + Pollack, M", " H", ", et al", " (2003)27 1 History of depression Venlafaxine vs placebo + 0 + + + + + + Stein, D", " J", ", Andersen, H", " F", ", and Goodman, W", " K", " (2005)20 0 baseline HAM-D17>12 (Above Median) Escitalopram vs Placebo + 0 + + + + + + DESENVOLVIMENTO 38 Rickels, K", ", et al", " (2013)19 0 Baseline HAM-D Venlafaxine + 0 + + 0 0 0 0 Substance abuse Pollack, M", " H", ", et al", " (2003)27 1 History of substance abuse Venlafaxine vs placebo Moderator of response to placebo + 0 + + + + + + Personality disorders Piero, A", " and Locati, E", " (2011)31 -1 Cluster C personality disorder Escitalopram vs Duloxetine 0 + + + + 0 0 0 Multiple diagnoses Ball, S", " G", ", et al", " (2005)36 0 Presence of a Comorbid condition Sertraline vs Paroxetine SAD, Panic Disorder, MDD, Dysthymia + + + + + 0 + + Panic disorder Rickels, K", ", et al", " (1993)29 0 HSCL phobic-panic factor 0 Imipramine vs Trazodone vs Diazepam vs Placebo divided at the median + + + + + + + + Pollack, M", " H", ", et al", " (2003)27 1 History of panic disorder Venlafaxine vs placebo > response to venlafaxine vs placebo at 24 weeks + 0 + + + + + + Neuroticism Downing, R", " W", " and Rickels, K", " (1985)18 0 Eysenck neuroticism Diazepam 10mg 0 0 + + U 0 0 0 Rickels, K", ", et al", " (1993)29 -1 Eysenck neuroticism >15 Imipramine vs Trazodone vs Diazepam vs Placebo Low neuroticism predicts better results in all groups and placebo + + + + + + + + Rickels, K", ", et al", " (2013)19 -1 Eysenck neuroticism Venlafaxine Low neuroticism increases chance of remission + 0 + + 0 0 0 0 Extroversion / Introversion Rickels, K", ", et al", " (2013)29 0 Eysenck extra-introversion", " Venlafaxine + 0 + + 0 0 0 0", "2", "1", "4", "4 Genetics Our search yielded five articles meeting inclusion criteria in which testing for genetic markers for treatment response was reported (Table 4)", " These studies were conducted with data from the same trial using open-label venlafaxine in a prospective design", " Each article reported on the measurement of fewer than five predictors, but since all the studies were taken from the same trial, more than five measurements were taken overall", " A strong predictive effect was found for a better treatment response in carriers of the G-allele single-nucleotide polymorphism rs7997012 of the serotonin receptor 2A gene (HTR2A)", "44 A dominant model of the Met variant of the catechol-o-methyltransferase gene (COMT)43 and carriers of the SNP rs2856966 of the pituitary adenylate cyclase-activating polypeptide gene (PACAP) were also slightly better responders", "45 The genes for the dopamine receptor D2, dopamine transporter 1, opioid receptor μ1, and PACAP type 1 receptor did not show significant associations", "45-47 DESENVOLVIMENTO 40 TABELA 4 - GENETIC PREDICTORS IN INCLUDED STUDIES", " Reference Gene Polymorphism Response Odds ratio Narasimhan et al", " (2012)43 COMT Val/Met (dominant Met) 1 3", "26 Lohoff et al", " (2013)44 HTR2A SNP rs7997012 G-allele (dominant model) 1 3", "32 Cooper et al", " (2013)45 PACAP SNP rs2856966 (dominant model) 1 1", "34 PAC1 SNP rs2267735 0 – Cooper et al", " (2013)46 OPRM1 A118G SNP A/G 0 – Saung et al", " (2014)47 DRD2 SNP rs1076560 0 – DRD2 SNP rs1800497 0 - DAT1 SNP rs255094 0 – DAT1 VNTR (10/10, 10/9, 9/9) 0 - Note: 1 = positive relationship; 0 = no relationship; OR = odds ratio; HTR2A = 5-hydroxytryptamine (serotonin) receptor 2A; COMT = Catechol-O-methyl transferase; PACAP = Pituitary adenylate cyclase-activating peptide; OPRM1 = opioid receptor, mu 1; PAC1 = Pituitary adenylate cyclase-activating peptide (PACAP) ligand/type 1 receptor; DRD2 = Dopamine receptor D2; DAT1 = Dopamine transporter; SNP = Single-nucleotide polymorphism; VNTR = Variable number tandem repeat DESENVOLVIMENTO 41 2", "1", "4", "5 Neuroimaging Two articles examined the predictor effect of brain activation during emotional tasks,48,49 followed by open-label treatment with venlafaxine XR", " Both stated a priori hypotheses and measured only brain activity as a whole as a predictor of treatment response (Table 5)", " In the first experiment, human faces showing different emotional expressions were presented to the subjects during functional magnetic resonance imaging acquisition", " In the fearful expression condition, anterior cingulate cortex activity was directly correlated with treatment response, whereas activity in the left amygdala showed an inverse correlation", " In the second study, subjects were exposed to aversive pictures (mutilated bodies, attack scenes) preceded by a visual cue", " During anticipation of negative images, anterior cingulate cortex activity also correlated with better treatment response", " TABELA 5 - FMRI PREDICTORS", " 2", "1", "5 Discussion This systematic review summarizes the current evidence on predictors and moderators of GAD treatment response to pharmacotherapy", " In our systematically selected sample, studies testing for at least one predictor were published later than those that did not, and studies designed to test for specific predictors were published even later than the ones that did not state Region Study Predictor Experiment Pearson’s r Anterior cingulate gyrus activity Whalen et al", " (2008)49 1 Exposure to fearful expressions 0", "61 Nitschke et al", " (2009)48 1 Anticipation to negative images 0", "76 Amygdala activity Whalen et al", " (2008)49 -1 Exposure to fearful expressions −0", "64 Nitschke et al", " (2009)48 0 Anticipation to negative images (Not significant) DESENVOLVIMENTO 42 a priori hypotheses about predictor effects", " This temporal order is consistent with the expected order in which these findings would be reported in the scientific literature and can be thus considered indirect evidence that the studies reported in this review represent a valid sample of current knowledge", " Studies reporting predictors of treatment response tended to be of weaker designs than traditional double-blind RCTs; they usually followed a prospective, open-label, single-arm design, which is not suitable for moderator analysis", " It is possible that unpublished trial data could increase the number and reliability of the predictors or moderators found, but none of the available evidence suggests selective reporting between industrial-sponsored versus investigator-initiated trials", " We are aware that the inclusion of non-randomized, single-arm, and naturalistic trials is uncommon in systematic reviews", " The added methodological complexity and stronger risk for bias do not allow definite conclusions about the strength of the effects", " This inclusion was not intended to be confirmatory of predictive effects, however; it was intended to provide future high-quality studies with relevant hypotheses about potential predictor variables", "50 The predictors reported in the studies meeting inclusion criteria were remarkably variable", " Sample sizes were relatively small and, in general, did not provide enough statistical power to consider negative results as evidence for a nonexistent effect", " The lack of power was a major limitation for most of the studies, precluding interaction analyses and the identification of clinically relevant moderator effects", " Taking a conservative stance, we could not find clear-cut evidence supporting any single strong predictor of drug treatment response in GAD", " Nevertheless, taking in account the quality of the hypotheses and data from other, better-studied Axis I disorders, such as major depression, a number of promising candidates deserve future confirmatory studies", " Although a few sociodemographic variables, such as sex and age, were more consistently tested, most findings were negative or ambiguous", " These results partially mirror DESENVOLVIMENTO DESENVOLVIMENTO 44 Neuroticism is characterized by a deficit in emotional regulation, represented by a stable tendency to experience aversive emotional states with increased arousal, a slow inhibition of responses to negative stimuli, and inefficient ways to cope with stress", "54 These abnormalities are reflected on neuroimaging studies, which found decreased activity in the anterior cingulate cortex and increased activity in the limbic regions during emotional processing tasks", "55 Neuroticism predicted poor treatment response in the two high-quality studies that tested for this interaction in GAD", " Taking into account that this temperament trait is also strongly associated with a worse outcome in major depressive disorder56,57 and was also predictive of persistent lifetime anxiety symptoms in a large cohort of patients with anxiety disorders,58 we consider neuroticism is likely associated with poor treatment response to pharmacotherapy in GAD", " It is not clear how high scores in neuroticism scales would account for worse outcomes in the treatment of GAD", " A number of neurotic traits, such as the tendency to be anxious, to worry, and to be “tense,”54 are similar to the core symptoms of GAD", " Assuming that these traits are stable across the duration of a typical clinical trial and that those personality traits are not substantially affected by treatment, it is reasonable to expect that patients with higher neuroticism scores finish the study without meaningful change in the shared traits, with the consequence that these patients endorse more GAD symptoms than patients with lower neuroticism scores", " Neuroticism is also associated with both increased exposure to stressful life events and less-efficient coping mechanisms, leading to an increased risk of psychopathology after stress exposure", "54,59 An overall increase in stress burden may partially mediate the negative impact of neuroticism on the treatment outcome of GAD", " Even with the strong limitation of overlapping populations, the genetic studies provide an interesting candidate for confirmatory studies", " The 5-HT2A receptor is associated with stress-induced psychopathology and impulsive behavior, and may be involved in emotion- DESENVOLVIMENTO 45 regulation processes in humans", "60 Receptor density in the medial prefrontal cortex is strongly associated with threat-related amygdala reactivity, habituation, and functional coupling with prefrontal regulatory regions, strongly indicating that 5-HT2A serotonergic transmission plays a key role in cortical regulation of limbic emotional responses", "61 Polymorphisms in the 5-HT2A receptor gene were previously reported as predicting treatment response in major depressive disorder in a meta-analysis by Kato and Serreti", "62 The single study on this question found a strong effect of the G allele in the rs7997012 polymorphism that was even more robust for carriers of two copies of the variation (odds ratio = 4", "98)", " It is possible for one of the variants to be more effective in facilitating cortical control of limbic regions, but no data are available yet on the biological effect of this polymorphism", " Although both COMT63 and PACAP64 have been implicated in emotion regulation and response, the small effect sizes and inconsistent effects limit the interpretation of those findings", " The most consistent finding in GAD neuroimaging studies is that patients fail to activate the anterior cingulate cortex and inhibitory prefrontal regions during emotion-regulation tasks, while showing an increased activation in the same regions during worry-induction tasks", " These experiments also show an increased activation of the amygdala in anticipation of neutral- and negative-emotion pictures, in line with the hypothesis that GAD patients have a chronic increase in limbic activity, associated with a general deficiency in top-down control of limbic regions", "65 Two studies meeting the inclusion criteria for the present review measured brain activity during emotion modulation as predictors of treatment response in GAD, and both found increased anterior cingulate cortex activity as having potential predictive value", "48,49 This result indicates that preserved emotion-regulation function by frontal structures may facilitate treatment response to venlafaxine", " The correlation between pretreatment activity in the anterior cingulate cortex and treatment response, however, is not specific to GAD", " Pretreatment medial prefrontal cortical DESENVOLVIMENTO 46 activity has also been correlated with treatment response in obsessive-compulsive disorder and posttraumatic stress disorder,9 and increased anterior cingulate activity is robustly correlated with treatment response to antidepressants in major depressive disorder, according to a meta-analysis of 23 different studies", "66 Activity in the amygdala was also associated, albeit less frequently, with treatment response in major depressive disorder, obsessive-compulsive disorder, and PTSD, using various treatment modalities", "9,10 Since the anterior cingulate cortex is thought to be responsible for the regulation of negative emotional states, specifically in detecting conflicting emotional information and recruiting cognitive resources involved in conflict resolution,67 and the amygdala is involved in the appraisal and control of emotional responses to threatening stimuli, Nitschke and colleagues48 proposed that a preserved regulatory capacity by these regions would be correlated with better treatment outcome, irrespective of the underlying disorder", " DESENVOLVIMENTO 47 2", "1", "6 Conclusion Given the substantial comorbidity, and overlapping symptomatology between GAD and major depressive disorder, it is perhaps not that surprising that the two disorders share some predictors of pharmacological treatment response", " Neuroticism, genetic, and neuroimaging findings may share a deficient mechanism in self-focused processing and in recruiting cognitive control in emotional situations", " A greater understanding of this mechanism could improve treatment outcomes independently of the underlying disorder", "9,66,68 The presence of subclinical depression (four of the five major depressive disorder criteria required for diagnosis) was the only variable found to moderate treatment outcome between two different interventions", " Clinicians should therefore continue actively questioning patients with GAD about depressive symptoms and prioritize treatment with antidepressants in those presenting with subclinical depression", " This review points to a few gaps in knowledge that future studies need to address more specifically", " (1) Studies comparing different drugs, such as pregabalin versus antidepressants, should test for moderator effects of major depressive disorder and other characteristics that could in the future be used to aid in selecting specific drug classes and to thereby improve overall efficacy for individual patients", " (2) New studies should address the prognostic value of neuroticism, anterior cingulate activity, and serotonin receptor genetics and whether these factors are independent or, instead, represent overlapping measurements of the same traits", " DESENVOLVIMENTO 48 2", "1", "7 References 1", " Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU", " Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States", " Int J Methods Psychiatr Res 2012;21:169-84", " 2", " Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J", " Generalized anxiety and depression in primary care: prevalence, recognition, and management", " J Clin Psychiatry 2002;63 Suppl 8:24-34", " 3", " Hoffman DL, Dukes EM, Wittchen HU", " Human and economic burden of generalized anxiety disorder", " Depress Anxiety 2008;25:72-90", " 4", " Endicott J, Russell JM, Raskin J, et al", " Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies", " J Clin Psychiatry 2007;68:518-24", " 5", " Bereza BG, Machado M, Ravindran AV, Einarson TR", " Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder", " Can J Psychiatry 2012;57:470-8", " 6", " Bystritsky A", " Treatment-resistant anxiety disorders", " Mol Psychiatry 2006;11:805-14", " 7", " Baldwin DS, Waldman S, Allgulander C", " Evidence-based pharmacological treatment of generalized anxiety disorder", " Int J Neuropsychopharmacol 2011;14:697-710", " 8", " Pincus T, Miles C, Froud R, Underwood M, Carnes D, Taylor SJ", " Methodological criteria for the assessment of moderators in systematic reviews of randomised controlled trials: a consensus study", " BMC Med Res Methodol 2011;11:14", " 9", " Shin LM, Davis FC, Vanelzakker MB, Dahlgren MK, Dubois SJ", " Neuroimaging predictors of treatment response in anxiety disorders", " Biol Mood Anxiety Disord 2013;3:15", " 10", " Olatunji BO, Ferreira-Garcia R, Caseras X, et al", " Predicting response to cognitive behavioral therapy in contamination-based obsessive-compulsive disorder from functional magnetic resonance imaging", " Psychol Med 2013:1-13", " 11", " Tukel R, Bozkurt O, Polat A, Genc A, Atli H", " Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder", " Psychiatry Clin Neurosci 2006;60:404-9", " 12", " Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L", " Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder", " Am J Psychiatry 1999;156:1409-16", " DESENVOLVIMENTO 49 13", " Bloch MH, Bartley CA, Zipperer L, et al", " Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive-compulsive disorder", " Mol Psychiatry 2014", " 14", " Dell'Osso B, Buoli M, Hollander E, Altamura AC", " Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder", " World J Biol Psychiatry 2010;11:59-65", " 15", " Slaap BR, den Boer JA", " The prediction of nonresponse to pharmacotherapy in panic disorder: A review", " Depress Anxiety 2001;14:112-22", " 16", " Freire RC, Perna G, Nardi AE", " Panic disorder respiratory subtype: psychopathology, laboratory challenge tests, and response to treatment", " Harv Rev Psychiatry 2010;18:220-9", " 17", " Maron E, Nutt D", " Biological predictors of pharmacological therapy in anxiety disorders", " Dialogues Clin Neurosci 2015;17:305-17", " 18", " Perlis RH", " A clinical risk stratification tool for predicting treatment resistance in major depressive disorder", " Biol Psychiatry 2013;74:7-14", " 19", " Uher R, Tansey KE, Dew T, et al", " An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline", " Am J Psychiatry 2014;171:1278-86", " 20", " Sun X, Briel M, Walter SD, Guyatt GH", " Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses", " BMJ 2010;340:c117", " 21", " R Core Team", " R: A Language and Environment for Statistical Computing", " Vienna, Austria: R Foundation for Statistical Computing; 2014", " 22", " Knopp J, Knowles S, Bee P, Lovell K, Bower P", " A systematic review of predictors and moderators of response to psychological therapies in OCD: do we have enough empirical evidence to target treatment? Clin Psychol Rev 2013;33:1067-81", " 23", " Moher D, Liberati A, Tetzlaff J, Altman DG", " Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementThe PRISMA Statement", " Ann Intern Med 2009;151:264-9", " 24", " Downing RW, Rickels K", " Early treatment response in anxious outpatients treated with diazepam", " Acta Psychiatr Scand 1985;72:522-8", " 25", " Feighner JP", " Buspirone in the long-term treatment of generalized anxiety disorder", " J Clin Psychiatry 1987;48 Suppl:3-6", " 26", " Pollack MH, Meoni P, Otto MW, Simon N, Hackett D", " Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies", " J Clin Psychopharmacol 2003;23:250-9", " 27", " Stein DJ, Andersen HF, Goodman WK", " Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes", " Ann Clin Psychiatry 2005;17:71-5", " DESENVOLVIMENTO 50 28", " Nicolini H, Bakish D, Duenas H, et al", " Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial", " Psychol Med 2009;39:267-76", " 29", " Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV", " Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial", " Eur Neuropsychopharmacol 2012;22:847-57", " 30", " Davidson JR, Bose A, Korotzer A, Zheng H", " Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study", " Depress Anxiety 2004;19:234-40", " 31", " Steiner M, Allgulander C, Ravindran A, Kosar H, Burt T, Austin C", " Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder", " Hum Psychopharmacol 2005;20:3-13", " 32", " Simon NM, Zalta AK, Worthington JJ, 3rd, et al", " Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder", " Depress Anxiety 2006;23:373-6", " 33", " Rickels K, Etemad B, Rynn MA, Lohoff FW, Mandos LA, Gallop R", " Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR", " Psychother Psychosom 2013;82:363-71", " 34", " Rickels K, Downing R, Schweizer E, Hassman H", " Antidepressants for the treatment of generalized anxiety disorder", " A placebo-controlled comparison of imipramine, trazodone, and diazepam", " Arch Gen Psychiatry 1993;50:884-95", " 35", " DeMartinis N, Rynn M, Rickels K, Mandos L", " Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder", " J Clin Psychiatry 2000;61:91-4", " 36", " Altamura AC, Dell'osso B, D'Urso N, Russo M, Fumagalli S, Mundo E", " Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder", " CNS Spectr 2008;13:415-22", " 37", " Piero A, Locati E", " An open, non-randomised comparison of escitalopram and duloxetine for the treatment of subjects with Generalized Anxiety Disorder", " Hum Psychopharmacol 2011;26:63-71", " 38", " Wurthmann C, Klieser E, Lehmann E", " Side effects of low dose neuroleptics and their impact on clinical outcome in generalized anxiety disorder", " Prog Neuropsychopharmacol Biol Psychiatry 1997;21:601-9", " 39", " Meoni P, Hackett D, Lader M", " Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder", " Depress Anxiety 2004;19:127-32", " 40", " Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D", " Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study", " Am J Psychiatry 2003;160:749-56", " DESENVOLVIMENTO 51 41", " Lader M, Scotto JC", " A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder", " Psychopharmacology (Berl) 1998;139:402-6", " 42", " Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW", " Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline", " J Clin Psychiatry 2005;66:94-9", " 43", " Narasimhan S, Aquino TD, Multani PK, Rickels K, Lohoff FW", " Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder", " Psychiatry Res 2012;198:112-5", " 44", " Lohoff FW, Aquino TD, Narasimhan S, Multani PK, Etemad B, Rickels K", " Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder", " Pharmacogenomics J 2013;13:21-6", " 45", " Cooper AJ, Narasimhan S, Rickels K, Lohoff FW", " Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder", " Psychiatry Res 2013;210:1299-300", " 46", " Cooper AJ, Rickels K, Lohoff FW", " Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder", " Hum Psychopharmacol 2013;28:258-62", " 47", " Saung WT, Narasimhan S, Lohoff FW", " Lack of influence of DAT1 and DRD2 gene variants on antidepressant response in generalized anxiety disorder", " Hum Psychopharmacol 2014;29:316-21", " 48", " Nitschke JB, Sarinopoulos I, Oathes DJ, et al", " Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response", " Am J Psychiatry 2009;166:302-10", " 49", " Whalen PJ, Johnstone T, Somerville LH, et al", " A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder", " Biol Psychiatry 2008;63:858-63", " 50", " Higgins JPT, Green S", " Cochrane Handbook for Systematic Reviews of Interventions: Wiley; 2008", " 51", " Esposito K, Goodnick P", " Predictors of response in depression", " Psychiatr Clin North Am 2003;26:353-65", " 52", " Yonkers KA, Dyck IR, Warshaw M, Keller MB", " Factors predicting the clinical course of generalised anxiety disorder", " Br J Psychiatry 2000;176:544-9", " 53", " Hirschfeld RMA", " The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care", " Prim Care Companion J Clin Psychiatry 2001;3:244-54", " 54", " Ormel J, Rosmalen J, Farmer A", " Neuroticism: a non-informative marker of vulnerability to psychopathology", " Soc Psychiatry Psychiatr Epidemiol 2004;39:906-12", " DESENVOLVIMENTO 52 55", " Servaas MN, van der Velde J, Costafreda SG, et al", " Neuroticism and the brain: A quantitative meta-analysis of neuroimaging studies investigating emotion processing", " Neurosci Biobehav Rev 2013;37:1518-29", " 56", " Clark LA, Watson D, Mineka S", " Temperament, personality, and the mood and anxiety disorders", " J Abnorm Psychol 1994;103:103-16", " 57", " Quilty LC, Meusel LA, Bagby RM", " Neuroticism as a mediator of treatment response to SSRIs in major depressive disorder", " J Affect Disord 2008;111:67-73", " 58", " Schuurmans J, Comijs HC, Beekman AT, et al", " The outcome of anxiety disorders in older people at 6-year follow-up: results from the Longitudinal Aging Study Amsterdam", " Acta Psychiatr Scand 2005;111:420-8", " 59", " Van Os J, Jones PB", " Early risk factors and adult person--environment relationships in affective disorder", " Psychol Med 1999;29:1055-67", " 60", " Stein DJ, Hemmings S, Moolman-Smook H, Audenaert K", " 5-HT2A: its role in frontally mediated executive function and related psychopathology", " CNS Spectr 2007;12:512-6", " 61", " Fisher PM, Meltzer CC, Price JC, et al", " Medial Prefrontal Cortex 5-HT2A Density Is Correlated with Amygdala Reactivity, Response Habituation, and Functional Coupling", " Cereb Cortex 2009;19:2499-507", " 62", " Kato M, Serretti A", " Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder", " Mol Psychiatry 2010;15:473-500", " 63", " Drabant EM, Hariri AR, Meyer-Lindenberg A, et al", " Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation", " Arch Gen Psychiatry 2006;63:1396-406", " 64", " Stevens JS, Almli LM, Fani N, et al", " PACAP receptor gene polymorphism impacts fear responses in the amygdala and hippocampus", " Proc Natl Acad Sci U S A 2014;111:3158-63", " 65", " Mochcovitch MD, da Rocha Freire RC, Garcia RF, Nardi AE", " A systematic review of fMRI studies in generalized anxiety disorder: Evaluating its neural and cognitive basis", " J Affect Disord 2014;167:336-42", " 66", " Pizzagalli DA", " Frontocingulate dysfunction in depression: toward biomarkers of treatment response", " Neuropsychopharmacology 2011;36:183-206", " 67", " Mayberg HS", " Targeted electrode-based modulation of neural circuits for depression", " J Clin Invest 2009;119:717-25", " 68", " Mayberg HS, Brannan SK, Mahurin RK, et al", " Cingulate function in depression: a potential predictor of treatment response", " Neuroreport 1997;8:1057-61", " DESENVOLVIMENTO 53 2", "2 ESTUDO 2 –AFETO NEGATIVO MEDIA A RELAÇÃO ENTRE O TAG E IMPULSIVIDADE", " Negative affect mediates increased impulsivity in generalized anxiety disorder Rafael Ferreira-Garcia, MD1, Clara Gitahy Falcão Faria1, Antonio Egídio Nardi, MD, PhD1, Rafael Christophe da Rocha Freire, MD PhD1,2 1 - Instituto de Psiquiatria - Universidade Federal do Rio de Janeiro 2 - Department of Psychiatry, School of Medicine, Queen's University", " Running Head: Negative affect and impulsivity in GAD Correspondence and reprints: Rafael Ferreira-Garcia Instituto de Psiquiatria - UFRJ Av", " Venceslau Brás, 71 Rio de Janeiro –RJ CEP: 22290-140 Email: rafaelfg@ipub", "ufrj", "br Submetido para a o periódico “Psychopathology”, em revisão, no momento", " Keywords: Generalized Anxiety Disorder; Impulsiveness; Negative Emotions; Anxiety, Symptom dimensions DESENVOLVIMENTO 54 2", "2", "1 Abstract Introduction: Although anxiety and impulsivity are intuitively thought to be inversely correlated, increased impulsivity has been associated both with generalized anxiety disorder (GAD) diagnosis and GAD symptoms in nonclinical samples", " The emotional dysregulation model of GAD posits that patients experience more frequent and intense negative emotions while having poor regulatory control over emotional states and greater negative reactivity to their emotions", " We hypothesized that that poor regulatory control in the presence of negative emotions might explain the increased impulsivity found in GAD patients", " In this study, we examined if negative affect mediates the relationship between GAD and impulsivity", " Methods: 34 GAD patients and 35 healthy controls were included, and evaluated with measurements of impulsivity, negative and positive emotions, the severity of worrying and GAD symptoms, depression, and five-factor personality traits", " Results: Global impulsivity scores and the attentional facet of impulsivity were higher in the patient group when compared to the controls", " Negative affect was correlated with global impulsivity in the patient group only and explained impulsivity in our regression model while worrying and depressive symptoms did not", " An indirect relationship was found between diagnosis and impulsivity through negative affect", " Conclusion: Our study showed that the cardinal symptom of GAD – worrying, was not independently related to impulsivity in our sample", " Increased impulsivity in GAD seems to be mediated by the increased presence of negative emotions, as it is common in mood and impulse-control disorders, indicating an unspecific shared vulnerability factor to psychopathology", " DESENVOLVIMENTO 55 2", "2", "2 Introduction Generalized Anxiety Disorder (GAD) is a chronic, debilitating condition, characterized by excessive and uncontrollable worrying and somatic tension", "[1] Etiological models for GAD include genetic and environmental vulnerabilities, but also individual dispositions and personality traits, such as the propensity to experience negative emotions (neuroticism), and harm avoidance", "[2] Those factors may interact in complex ways with GAD, at the same time sharing overlapping genetic vulnerabilities,[3] being prodromal symptoms and interfering in the course and prognosis of GAD patients", "[4,5] Impulsivity is an “individual predisposition toward rapid, unplanned reactions to internal or external stimuli without regard to the negative consequences of these reactions,” or acting without thinking", "[6] It is a relatively stable lifelong trait that is highly heritable and is associated with an unspecific increased risk for externalizing mental disorders, making a strong contender to play a role as an endophenotype", "[7,8] Although consistent as a unitary construct, internal factor structures of impulsivity have been proposed by different authors", " Barratt’s conceptualization decomposes impulsivity in three second-order factors: 1", " Attentional impulsiveness - an inability to focus attention or to concentrate 2", " Motor Impulsiveness – acting without thinking, and 3", " Non-planning – lack of forethought or inability to plan", "[9] Understanding the relative contribution of each subscale to the individual level of impulsivity may be useful for the identification of distinct phenotypes in the study of mental disorders", " The association between impulsivity and anxiety seems somewhat counterintuitive since the two constructs are classically considered orthogonal or inversely related", "[10] However, newer evidence shows that increased reported impulsivity is associated both with anxiety symptoms[11] and with a diagnosis of anxiety disorders in non-clinical population samples", "[12] Experimental evidence also indicates that individuals with high trait anxiety may perform more impulsively in a delayed-choice task", "[13] Few studies, however, have examined DESENVOLVIMENTO 56 the role of impulsivity in primary anxiety disorders", " In a study by Summerfeldt et al", ",[14] self-reported impulsivity was higher in patients with panic disorder, social anxiety disorder, and obsessive-compulsive disorder when compared to control individuals, although only the attentional factor of the Barrat Impulsiveness Scale (BIS-11) was different between groups", " Del Carlo et al", " [15] replicated these results, showing that a group of patients with mixed anxiety disorders was not only more impulsive than the control group in self-reported measures, but also had corresponding neuropsychological deficits, as measured by the Immediate and Delayed Memory Task and the Continuous Performance Task", " Impulsivity measures were also increased in GAD patients in a large population-based study, a relationship that was fully mediated by the presence of affect dysregulation", "[16] The prototypical patient with GAD is characterized by a general disposition to fear and active avoidance of risk-taking, besides the cardinal worry symptoms", "[17] These contrast sharply with the traits classically associated with impulsivity, namely, novelty-seeking, risk-taking, and acting without forethought", "[18] Nevertheless, increased impulsivity was shown in patients with GAD without MDD, similarly to patients with MDD without GAD, while patients with comorbid MDD and GAD reported somewhat higher impulsivity scores", "[19] GAD patients may display increases in only specific impulsivity facets or specific conditions", " Studies of non-clinical populations showed that subjects screening positive for GAD scored higher than control subjects in negative urgency, the dimension of impulsivity defined by the tendency to act thoughtlessly when distressed", " There were mixed results in the dimensions of lack of premeditation, sensation seeking, and lack of perseverance", "[18,20,21] The emotional dysregulation model of GAD posits that patients experience more frequent and intense negative emotions, that is, negative affect (NA) while having poor regulatory control over emotional states and greater negative reactivity to their emotions", "[22] More specifically, subjects with higher scores in GAD symptoms reported poorer impulse DESENVOLVIMENTO 57 control when upset, mirroring the findings of increased negative urgency", "[23] Nevertheless, it is not clear whether the presence of negative affect explains impulsivity in patients with GAD", " This study aims to explore the relationship between impulsivity and GAD", " We hypothesized that 1: patients with GAD would be more impulsive than healthy controls", " 2: Negative affect would be correlated with impulsivity in the patient, but not in control groups, and 3: the effect of GAD diagnosis in impulsivity scores would be mediated by negative affect", "", "DESENVOLVIMENTO 58 2", "2", "3 Materials and Methods: We recruited patients from the GAD outpatient clinic of the Anxiety and Depression research program in the Institute of Psychiatry of the Federal University of Rio de Janeiro", " Subjects between 18 and 65 years of age meeting current criteria for GAD according to the DSM IV criteria were included", " The exclusion criteria were: comorbid psychotic disorders, bipolar disorder, severe personality disorders, mental disorders due to a general medical condition and an inability to understand the consent procedures", " The control group consisted of 35 healthy volunteers with no current psychiatric disorders, recruited mainly from online advertisement for research controls, but also from a heterogeneous pool of university staff, graduate, and undergraduate students", " After informed consent, subjects were evaluated using the Brazilian Portuguese version of the Mini Neuropsychiatric Interview (MINI) 5", "0,[24] and all GAD were confirmed by a senior psychiatrist (RFG or RCRF)", " All self-report questionnaires were collected in their respective Brazilian Portuguese versions", " General GAD symptoms were measured using the GAD-7, a seven-item scale that has excellent psychometric properties as a severity measure for anxiety symptoms, as it correlates well with both clinician-administered and quality of life measures", "[25,26] Worrying severity, the cardinal symptom of GAD, was explicitly accessed by the Penn-State Worry Questionnaire (PSWQ), which evaluates worry as a unidimensional construct and was shown to be uncorrelated with state or trait anxiety symptoms", "[27,28] The Beck Depression Inventory (BDI), was used to evaluate the severity of depressive symptoms, as it provides scores that correlate with clinician measurements of depression, but not anxiety", "[29] Impulsivity was assessed using Barratt’s Impulsiveness Scale (BIS-11), which measures three facets of impulsivity: Motor, Cognitive, and Non-planning,[30] and has acceptable to good reliability for each subscale", "[31] Negative and positive affectivity were DESENVOLVIMENTO 59 measured using the Positive and Negative Affect Schedule (PANAS), which is a 10-item, self-report measure of positive and negative affect (NA)", "[32] Personality factors were measured using a list of trait-describing adjectives developed in Brazilian Portuguese by Hutz et al", " [33] to be equivalent to the extensively used adjective lists developed by Goldberg et al", "[34] It has been shown to replicate the Big-Five factor structure in factor analyses reliably and to have good internal consistency for each of the factors", " The scale is composed by 93 personality descriptors for which the subject is asked to rate “how much it describes yourself appropriately,” yielding scores for openness to experience, conscientiousness, extraversion, agreeableness, and neuroticism", " Normality and equality of variance of continuous variables were verified using Shapiro-Wilk and Levene’s tests, respectively", " Between-group central tendencies were compared using independent sample T-tests", " When the normality or equality of variances was violated, Welch’s test was used", " ANCOVA was performed to correct for potential confounders in the relationship between categorical and continuous variables", " Correlations were tested using either Pearson’s or Spearman’s, according to the distribution of the data", " Between-group correlations magnitudes were compared using the COCOR package for R", "[35] DESENVOLVIMENTO 60 2", "2", "4 Results Sixty-nine subjects (34 patients and 35 controls) were included in the study", " Demographic variables (age, sex, and educational level distribution) were similar between groups, as shown in Table 1", " Comorbidity was frequent in the GAD group, as usual when evaluated by the MINI", " Major depressive disorder was present in 10 (29", "4%) patients", " Most patients (55", "9%) had at least one additional anxiety disorder diagnosis, mainly panic disorder (38", "2%), agoraphobia (29", "4%) and social anxiety disorder (23", "5%)", " Obsessive-compulsive disorder criteria were met by 17", "4% of our patients", " 76", "5% of patients were in current use of pharmacological treatment, all of which were treated with at least one antidepressant drug, in therapeutic doses", " 35", "3% of patients were also in regular benzodiazepine use", " TABELA 6 - TABLE 1", " GAD Control Statistic p Sex, n (%) Female 24 (68", "6) 26 (76", "5) Fisher 0", "592 Male 11 (31", "4) 8 (25", "5) Total 35 34 Age, median (range) 33 (39) 33 (44) U = -1", "174 0", "247 Education, n (%) χ2 = 1", "1253 0", "569 < high school 1 (2", "94) 3 (8", "57) high school 9 (26", "47) 10 (28", "57) > university 24 (70", "59) 22 (62", "85) Study sample characteristics", " GAD: Generalized anxiety disorder, U: Mann-Whitney U", " χ2: Chi-square test", " Clinical measurements comparisons are shown in Table 2", " As expected, patients scored higher on the GAD-7, PSWQ, and BDI when compared to the control group, all comparisons revealing large effect sizes", " BIS scores were higher on the patient group when compared to control subjects, with moderate effect size", " When comparing second-order factors, only attentional impulsivity was different between groups, also showing a large effect size", " Patients also scored higher in the neuroticism subscale, with large effect size, while no DESENVOLVIMENTO 61 differences were found in the other dimensions of the five-factor model: conscientiousness, agreeableness, extraversion, or openness", " TABELA 7 - TABLE 2", " GAD Control Welch’s p GAD-7 12", "27 (5", "49) 4", "29 (3", "49) -7", "184 < ", "001 PSWQ 66", "97 (13", "30) 50", "14 (12", "60) -5", "393 < ", "001 BDI 16", "00 (7", "71) 6", "11 (4", "75) -6", "392 < ", "001 BIS 68", "50 (10", "966) 60", "44 (10", "177) -3", "104 0", "003 Attentional 21", "53 (4", "223) 16", "17 (4", "756) -4", "952 < ", "001 Motor 20", "97(4", "387) 20", "00 (4", "399) -0", "918 0", "362 Nonplanning 26", "00 (5", "908) 24", "37 (4", "678) -1", "267 0", "210 Big Five Conscientiousness 5", "154 (0", "777) 5", "254 (1", "022) 0", "462 0", "646 Neuroticism 3", "855 (1", "113) 2", "445 (0", "781) -6", "076 < ", "001 Agreeableness 5", "244 (0", "901) 5", "366 (0", "995) 0", "533 0", "596 Extraversion 4", "291 (1", "232) 4", "311 (1", "102) 0", "072 0", "943 Openness 4", "639 (0", "940) 4", "531 (1", "134) -0", "435 0", "665 PANAS Positive Affect 30", "44 (7", "04) 30", "00 (7", "568) 1", "322 0", "191 Negative Affect 26", "32 (8", "713) 15", "95 (7", "798) -6", "124 <0", "001 Clinical, impulsivity and personality measurements of patients and controls", " Statistically significant p values are highlighted", " To evaluate patient status effects on impulsivity using only second-order factors, we performed a one-way between-subjects multivariate analysis of variance (MANOVA) using the three-second order subscales (attention, motor, and nonplanning) as dependent variables", " The combined subscales were significantly different between groups (Pillai test = 0", "281, p < 0", "001) BIS scores were significantly correlated with GAD-7, PSWQ, BDI, Negative Affect, Neuroticism and inversely with Conscientiousness across the whole sample", " When taken as individual groups, only Conscientiousness was significantly correlated with BIS in both groups (patients: r = -0", "490, p = 0", "003, controls: r = -0", "569, p < ", "001)", " Negative affect scores were strongly correlated with BIS in the patient group (r = 0", "473, p = 0", "005) but not in the control group (r = 0", "053, p = 0", "767)", " The correlation coefficient was significantly higher in the patient DESENVOLVIMENTO Scatterplot of total BIS scores versus Negative Affect (NA) in Controls and GAD patients", " Impulsivity was correlated with NA exclusively in the GAD group", " Correlation indices were significantly different between groups", " Multiple regression analyses were performed to control for the effect of confounding variables in the effects of group belonging on BIS and BIS attentional facet (Table 3)", " Since age, gender and educational status are known correlates of impulsivity, they were included in the null model, along with conscientiousness", " For the full BIS score, in the first model, GAD status was a significant predictor of impulsivity p = 0", "002, explaining an additional 10", "2% of the variance (delta R2 = 0", "1021, F=10", "13, p = 0", "002)", " When NA and the PSWQ were included in the model, only NA significantly predicted impulsivity while the model explained ●●", "4050607080BISNegative AffectGroup●GADControl", "DESENVOLVIMENTO 63 significantly more variance than the model, including only the GAD status (delta R2 = 0", "068, F=3", "70, p = 0", "031)", " The addition of BDI did not increase the variance explained by the model and BDI was not a significant predictor of BIS (R2 = 0", "000, F=0", "026, p = 0", "87)", " Although the inclusion of neuroticism in the model nullified the effects of NA, it was not superior to the model including NA, PSWA and Group only, (delta R2 = 0", "017, F=1", "86, p = 0", "17), while adding substantial multicollinearity (VIF > 2", "5 for NA and Neuroticism)", " For the attentional component of the BIS, GAD status significantly improved the model explained variance by 23", "1% (delta R2 = 0", "231, F=27", "66, p < 0", "001)", " NA and PSWQ inclusion performed significantly better (delta R2 = 0", "098, F=7", "072, p = 0", "002)", " In the latter model, both PSWQ and NA were independently explanatory of attentional impulsivity, while the effect of GAD status became nonsignificant", " BDI scores were not significantly associated with Attentional impulsivity, nor its addition improved the explanatory power of the model (delta R2 = 0", "001, F=0", "242, p = 0", "625)", " TABELA 8 - TABLE 3 95% Confidence Interval Model Estimate SE Lower Upper t p BIS GAD – Control 2", "3883 2", "9238 -3", "4622 8", "239 0", "817 0", "417 Negative Affect 0", "3718 0", "1701 0", "0314 0", "712 2", "186 0", "033 PSWQ 0", "0698 0", "1020 -0", "1342 0", "274 0", "685 0", "496 BIS Attention GAD – Control 2", "20734 1", "1855 -0", "16491 4", "5796 1", "862 0", "068 Negative Affect 0", "13845 0", "0690 4", "47e-4 0", "2764 2", "007 0", "049 PSWQ 0", "09097 0", "0413 0", "00824 0", "1737 2", "200 0", "032 Multiple regression models of the BIS total scale and BIS attention subscale", " Significant values are highlighted", " Negative affect predicts the complete BIS scores and the attention factor, while the PSWQ only predicts the attention factor", " SE: Standard error", " GAD-Control: binary status as a patient/healthy control", " DESENVOLVIMENTO 64 Mediation analyses were performed to identify the direct and indirect effects of GAD diagnosis on BIS scores", " We initially performed multiple regression analyses of BIS as the dependent variable against each potential mediator as an independent variable separately, while correcting for the presence or absence of GAD", " In this step, only negative affect remained significant (Beta = 0", "368, p = 0", "009)", " The PSWQ (Beta = 0", "177, p = 0", "197), or BDI (Beta = 0", "147, p = 0", "316) did not survive correction for group belonging", " Group total effect on BIS was c = 0", "35 (p = 0", "0028), but direct effects were not significant after removing negative affect c’ = 0", "14 (p = 0", "38)", " The indirect effect through negative affect was ab = 0", "22 (p = 0", "0004, CI95% from 0", "05 to 0", "4, for 5000 bootstrapped samples), showing that the effect of the diagnosis on the BIS scores is fully mediated by the intensity of negative affect (Figure 2)", " We tested the inverse model, in which NA’s effect on impulsivity is mediated by group belonging", " Total effect of NA c = 0", "45 (p = 0", "00011), c' = 0", "37 (p = 0", "0087), while mediated effect through group did not reach significance, hinting at unidirectionality", " FIGURA 2 - FIGURE 2: Standardized regression coefficients and p-values for the relationship between group and impulsivity, mediated by negative affect", " GAD vs ControlBISNegative Affectb = 0", "37(p = 0", "009)a = 0", "6(p < 0", "001)Indirect effect: ab = 0", "22(p < 0", "001)Direct effect: c’ = 0", "14 (p = 0", "32) DESENVOLVIMENTO 65 2", "2", "5 Discussion Our results confirm our hypothesis that individuals with GAD report increased impulsivity in general when compared to healthy controls, which is specially related to the attentional facet of the BIS", " We also confirmed the hypothesis that negative affect correlated with impulsivity scores only in the patient subgroup and that NA mediates the effect of GAD diagnosis in self-reported impulsivity", " Our findings shed some light on the paradoxical observation that patients with GAD report more impulsivity than healthy controls", " Firstly, although worrying is the cardinal symptom of GAD, its relationship with impulsivity is by no means straightforward", " In our sample, worrying had an independent explanatory effect only in the attentional/cognitive facet of impulsivity and did not mediate global impulsivity", " Pathological worry is characterized by excessive worry that is difficult to control, so it is expected that be correlated with attentional impulsivity, which represents poor control over one’s thoughts and attention focus", " It is not surprising, therefore, that difficulty concentrating is one of the diagnostic criteria for GAD [1]", " In a study by Stefanopoulou and colleagues, experimentally induced worrying depleted global attentional resources in patients with GAD, but not in healthy controls, in an experiment sensitive to task difficulty [36]", " Working memory, a component directly related to attention, was also shown to be decreased by the verbal component of worrying in people scoring high in worrying from a general population sample [37]", " Our findings corroborate the experimental results and indicate that worrying may be related to impulsivity mainly through the attentional facet", " Global impulsivity was also increased in the GAD group, but it was not explained through worrying severity but by NA scores", " Also, as hypothesized, NA scores correlated with impulsivity in GAD patients, but not in healthy controls", " Our results also indicate that patients with GAD are more impulsive through the increase in negative emotions, meaning that the DESENVOLVIMENTO 66 increase in negative affect may be a necessary condition to increased impulsivity in this group of patients", " These findings are in line with our initial hypothesis that the presence of negative emotions would increase impulsivity in GAD", " Negative urgency, or the propensity to impulsive behaviors in the presence of negative emotions, has already been shown to be higher in a sample of undergraduate students screening positive for GAD when compared to controls from the same population[21]", " Pawluk and Koerner also showed that negative urgency was related to GAD symptoms indirectly through tolerance to distress and intolerance to uncertainty", "[18] Our findings partially corroborate that relationship and hints that the increase in negative affect derived by distress and uncertainty may be responsible for increased impulsivity", " Since GAD patients also report a lower tolerance to negative affect and poor regulation of negative emotions, it becomes less surprising that patients with GAD would be more impulsive than the general population", " The relationship between NA and impulsivity is not unique to GAD", " NA is associated with increased experimental measurements of impulsivity in nonclinical samples", "[38] Negative urgency is also widely studied in impulse control and related disorders", " It is associated with a large number of impulsive behaviors, such as alcohol use, risky sexual behavior, illegal drug use, tobacco use, and gambling", "[39] Negative urgency also seems to predict independently future impulsivity and depressive symptoms, being a potentially shared risk-factor between emotional and impulsive psychopathology", "[39] GAD is highly comorbid, and also shares many clinical features with depression and other anxiety disorders", " Our study showed that the cardinal symptom of GAD – worrying, was not independently related to impulsivity in our sample", " It is possible, therefore, that impulsivity in GAD is partially due to an unspecific shared vulnerability factor to psychopathology, and not due to specific characteristics of GAD", " The authors are aware of the limitations of this study", " Although the hypothesized effects were present and significant in our sample, our relatively small n of 69 participants could DESENVOLVIMENTO 67 increase the chance of type II errors and is not suitable to statistical methods involving the interaction of a higher number of variables", " We also did not collect a specific measure of negative urgency, which would help determine if the NA effect on impulsivity was analogous to the increased measurements of negative urgency found in patients with GAD", " Another significant limitation is that most of our GAD patients were under pharmacological treatment", " Although we could not find a significant relationship between drug treatment and impulsivity, our study is probably underpowered to make strong claims on that possible confounding factors", " This study indicates that NA mediates the increased impulsivity found in GAD patients, and not worrying or depressive symptoms", " Future studies are needed to further clarify the relationship between impulsivity and negative emotions in patients with GAD", " Experimental studies provoking negative emotions while measuring different aspects of impulsivity are required to confirm the self-report findings", " Also, prospective studies of larger samples are needed to test for causal relationships between GAD, neuroticism, NA, and impulsivity", " DESENVOLVIMENTO 68 Acknowledgments The authors are gratefull for the support of the Institute of Psychiatry’s staff on providing the infrastructure for the development of this work", " Statement of Ethics: All subjects were thoroughly informed and have given written consent to participate in the research", " This research project was approved by the local Ethics Committee, under the CAAE number: 32321414", "2", "0000", "5263", " Disclosure Statement: RFG is an employee of the Federal University of Rio de Janeiro and had a research scholarship from CAPES", " Ms", " CGFF has a research scholarship from the Federal University of Rio de Janeiro, RCRF and AEN are employees of the Federal University of Rio de Janeiro and received research scholarships from CNPq, FAPERJ and CAPES", " The authors report no conflicts of interest", " Funding Sources: This research has received no external funding", " Author Contributions: RFG, AEN and RCRF have participated in the conception and planning of the study, RFG and CGFF have performed the acquisition and analysis of the data", " All authors participated in the interpretation of the results", " RFG has written the draft manuscript, which was revised and supplemented by all authors", " All authors approve the final manuscript and stand by the findings and conclusions", " The authors alone are responsible for the content and writing of the article DESENVOLVIMENTO 69 2", "2", "6 References: 1 1 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition", " Arlington, VA, American Psychiatric Publishing, 2013", " DOI: 10", "1176/appi", "books", "9780890425596", "744053 2 Stein DJ [Ed], Hollander E [Ed], Rothbaum BO [Ed]: Textbook of anxiety disorders (2nd ed", ")", " ed 2nd Arlington, VA, American Psychiatric Publishing, 2010", " DOI: 10", "1017/CBO9781107415324", "004 3 Hettema JM, Prescott CA, Kendler KS: Genetic and environmental sources of covariation between generalized anxiety disorder and neuroticism", " Am J Psychiatry 2004;161:1581–1587", " 4 Brandes M, Bienvenu OJ: Personality and anxiety disorders", " Curr Psychiatry Rep 2006;8:263–269", " 5 Ferreira-Garcia R, Mochcovitch M, do Cabo MC, Nardi AE, Freire RC: Predictors of Pharmacotherapy Response in Generalized Anxiety Disorder: A Systematic Review", " Harv Rev Psychiatry 2017;25:65–79", " 6 Bari A, Robbins TW: Inhibition and impulsivity: Behavioral and neural basis of response control", " Prog Neurobiol 2013;108:44–79", " 7 Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC: Psychiatric aspects of impulsivity", " Am J Psychiatry 2001;158:1783–1793", " 8 Pierò A: Personality correlates of impulsivity in subjects with generalized anxiety disorders", " Compr Psychiatry 2010;51:538–545", " 9 Stanford MS, Mathias CW, Dougherty DM, Lake SL, Anderson NE, Patton JH: Fifty years of the Barratt Impulsiveness Scale: An update and review", " Pers Individ Dif 2009; DOI: 10", "1016/j", "paid", "2009", "04", "008 10 Barratt ES: Factor Analysis of Some Psychometric Measures of Impulsiveness and DESENVOLVIMENTO 70 Anxiety", " Psychol Rep 1965;16:547–554", " 11 Moustafa AA, Tindle R, Frydecka D, Misiak B: Impulsivity and its relationship with anxiety, depression and stress", " Compr Psychiatry 2017;74:173–179", " 12 Chamorro J, Bernardi S, Potenza MN, Grant JE, Marsh R, Wang S, et al", ": Impulsivity in the general population: A national study", " J Psychiatr Res 2012;46:994–1001", " 13 Xia L, Gu R, Zhang D, Luo Y: Anxious Individuals Are Impulsive Decision-Makers in the Delay Discounting Task: An ERP Study", " Front Behav Neurosci 2017;11:1–11", " 14 Summerfeldt LJ, Hood K, Antony MM, Richter MA, Swinson RP: Impulsivity in obsessive-compulsive disorder: Comparisons with other anxiety disorders and within tic-related subgroups", " Pers Individ Dif 2004;36:539–553", " 15 Del Carlo A, Benvenuti M, Fornaro M, Toni C, Rizzato S, Swann AC, et al", ": Different measures of impulsivity in patients with anxiety disorders: A case-control study", " Psychiatry Res 2012;197:231–236", " 16 Peters EM, Bowen R, Balbuena L: Mood instability contributes to impulsivity, non-suicidal self-injury, and binge eating/purging in people with anxiety disorders", " Psychol Psychother Theory, Res Pract 2018;8:422–438", " 17 Woody S, Rachman S: Generalized anxiety disorder (GAD) as an unsuccessful search for safety", " Clin Psychol Rev 1994;14:743–753", " 18 Pawluk EJ, Koerner N: The relationship between negative urgency and generalized anxiety disorder symptoms: the role of intolerance of negative emotions and intolerance of uncertainty", " Anxiety Stress Coping 2016;29:606–615", " 19 Trofimova I, Sulis W: There is more to mental illness than negative affect: Comprehensive temperament profiles in depression and generalized anxiety", " BMC Psychiatry 2018;18:1–17", " 20 Miller J, Flory K, Lynam D, Leukefeld C: A test of the four-factor model of impulsivity- DESENVOLVIMENTO 71 related traits", " Pers Individ Dif 2003;34:1403–1418", " 21 Pawluk EJ, Koerner N: A preliminary investigation of impulsivity in generalized anxiety disorder", " Pers Individ Dif 2013;54:732–737", " 22 Mennin DS, Heimberg RG, Turk CL, Fresco DM: Preliminary evidence for an emotion dysregulation model of generalized anxiety disorder", " Behav Res Ther 2005;43:1281–1310", " 23 Salters-Pedneault K, Roemer L, Tull MT, Rucker L, Mennin DS: Evidence of broad deficits in emotion regulation associated with chronic worry and generalized anxiety disorder", " Cognit Ther Res 2006;30:469–480", " 24 Amorim P: Mini International Neuropsychiatric Interview ( MINI ): validação de entrevista breve para diagnóstico de transtornos mentais Mini International Neuropsychiatric Interview ( MINI ): validation of a short structured diagnostic psychiatric interview 2000;22", " 25 Sousa T V, Viveiros V, Chai M V, Vicente FL, Jesus G, Carnot MJ, et al", ": Reliability and validity of the Portuguese version of the Generalized Anxiety Disorder (GAD-7) scale", " Health Qual Life Outcomes 2015;13:50", " 26 Spitzer RL, Kroenke K, Williams JBW, Löwe B: A brief measure for assessing generalized anxiety disorder: The GAD-7", " Arch Intern Med 2006;166:1092–1097", " 27 Castillo C, Macrini L, Cheniaux E, Landeira-Fernandez J: Psychometric properties and latent structure of the Portuguese version of the Penn State worry questionnaire", " Span J Psychol 2010;13:431–443", " 28 Brown TA, Antony MM, Barlow DH: Psychometric properties of the Penn State worry questionnaire in a clinical anxiety disorders sample", " Behav Res Ther 1992;30:33–37", " 29 Gorenstein C, Andrade L: Validation of a Portuguese version of the Beck Depression Inventory and the State-Trait Anxiety Inventory in Brazilian subjects", " Brazilian J Med DESENVOLVIMENTO 72 Biol Res = Rev Bras Pesqui medicas e Biol 1996;29:453–457", " 30 Von Diemen L, Szobot CM, Kessler F, Pechansky F: Adaptation and construct validation of the Barratt Impulsiveness Scale (BIS 11) to Brazilian Portuguese for use in adolescents", " Rev Bras Psiquiatr 2007;29:153–156", " 31 Patton JH, Stanford MS, Barratt ES: Factor structure of the Barratt impulsiveness scale", " J Clin Psychol 1995;51:768–774", " 32 Carvalho HW de, Andreoli SB, Lara DR, Patrick CJ, Quintana MI, Bressan RA, et al", ": Structural validity and reliability of the Positive and Negative Affect Schedule (PANAS): evidence from a large Brazilian community sample", " Rev Bras Psiquiatr 2013;35:169–172", " 33 Hutz CS, Nunes CH, Silveira AD, Serra J, Anton M, Wieczorek LS: O desenvolvimento de marcadores para a avaliação da personalidade no modelo dos cinco grandes fatores", " Psicol Reflexão e Crítica 1998;11:395–411", " 34 Goldberg LR: The development of makers of the Big-Five factor structure", " Psychological Assess 1992;4:26–42", " 35 Diedenhofen B, Musch J: cocor : A Comprehensive Solution for the Statistical Comparison of Correlations 2015;1–12", " 36 Stefanopoulou E, Hirsch CR, Hayes S, Adlam A, Coker S: Are attentional control resources reduced by worry in generalized anxiety disorder? J Abnorm Psychol 2014;123:330–335", " 37 Leigh E, Hirsch CR: Worry in imagery and verbal form: Effect on residual working memory capacity", " Behav Res Ther 2011;49:99–105", " 38 Patterson TK, Lenartowicz A, Berkman ET, Ji D, Poldrack RA, Knowlton BJ: Putting the brakes on the brakes: negative emotion disrupts cognitive control network functioning and alters subsequent stopping ability", " Exp brain Res 2016;234:3107–3118", " DESENVOLVIMENTO 73 39 Smith GT, Cyders MA: Integrating affect and impulsivity: The role of positive and negative urgency in substance use risk", " Drug Alcohol Depend 2016;163:S3–S12", "", "DESENVOLVIMENTO 74 Estudo 3 – Comorbidades no TDAH – transtornos de ansiedade, transtorno obsessivo-compulsivo e transtorno de estresse pós-traumático Capítulo de livro publicado em: Nardi AE, Quevedo J, da Silva AG: Transtorno de déficit de atenção/hiperatividade: Teoria e clínica. Artmed Editora, 2015.", "DESENVOLVIMENTO 75 2.2.7 Introdução A ansiedade pode ser definida como um estado emocional difuso, desagradável, relacionado à apreensão sobre o possível surgimento de um evento futuro incômodo ou perigoso. Sintomas físicos, como palpitação, dispneia e sudorese, em conjunto com elementos cognitivos, como ruminações, hipervigilância a ameaças, e pensamentos catastróficos são componentes da experiência afetiva de ansiedade.1 Essas reações fazem parte da resposta normal a uma ameaça física real, porém são características dos transtornos de ansiedade quando presentes de maneira repetitiva ou crônica, mesmo na ausência de um perigo real. Fenômenos como medos, ansiedade de separação e compulsões/obsessões são comuns na infância, e, quando se apresentam de forma moderada, sem prejuízo às atividades diárias e com curso fugaz, podem ser considerados elementos normais e até esperados do desenvolvimento humano. A exacerbação desses sintomas, seja em intensidade, prejuízo nas atividades diárias ou duração, deve, no entanto, alertar para a presença de um transtorno de ansiedade subjacente.2 Os transtornos de ansiedade estão entre as condições psiquiátricas mais comuns em crianças e adolescentes. São causa de importante prejuízo funcional que é especialmente intenso no funcionamento familiar, mas também presente no relacionamento com pares, atividades escolares e de lazer.3 Tendem a ser crônicos, mantendo pior funcionamento global durante a adolescência, e possivelmente até a vida adulta.4 Além disso, a comorbidade é comum entre portadores. Estima-se que 40 a 60% das crianças ansiosas preenchem critérios para mais de um transtorno de ansiedade, além de apresentarem maior risco global para transtornos do humor.4 Crianças portadoras de transtorno de déficit de atenção/ hiperatividade (TDAH) são especialmente vulneráveis, com prevalência variando entre 15 e 35% de ao menos um transtorno de ansiedade em contraste com 5 a 15% da população geral.5,6 De maneira mais DESENVOLVIMENTO DESENVOLVIMENTO 77 De modo geral, os sintomas de ansiedade parecem estar correlacionados com características clínicas menos impulsivas, mas não indicam menor interferência nas atividades cotidianas ou melhor prognóstico. Também é importante ressaltar que, embora interessantes para fins de pesquisa, as diferenças detectadas não apresentam magnitude suficiente para serem úteis para fins diagnósticos.10 2.2.9 Avaliação da ansiedade no TDAH A alta prevalência de ansiedade, com prejuízo associado, torna necessária a avaliação desses sintomas em todas as crianças com diagnóstico de TDAH. Durante o exame, o avaliador deve buscar a ocorrência de um estado de alerta, com emoção negativa, em resposta a ameaças externas. Isto é, deve perguntar sobre situações que deixem a criança “assustada”, “preocupada” ou “ansiosa”. Devem ser examinados especificamente diversos temas, conforme a idade e o contexto, incluindo-se atividades escolares, situações sociais, atitude ante notícias, saúde da própria criança ou de parentes, ou objetos e animais. A literatura demonstra consistentemente uma discordância entre os relatos dos pais e das crianças sobre os sintomas de ansiedade. Os pais tendem a valorizar sintomas observáveis, como inquietude e insônia, enquanto os sintomas “internos”, como preocupações e tensão muscular, são pouco perceptíveis.11 O examinador deve estar atento também à confusão comum entre ansiedade e agitação/hiperatividade, que deve ser suspeitada quando os exemplos de ansiedade dados pelos pais são restritos ao aumento da atividade motora. Prover um breve esclarecimento sobre a natureza dos sintomas ansiosos costuma, nesses casos, resultar na coleta de dados mais precisos. As crianças, por sua vez, tendem a enviesar a sua descrição para comportamentos que consideram gerar maior aprovação do examinador, muitas vezes omitindo comportamentos de segurança ou evitação.11 Tendo-se em mente a natureza discrepante dos DESENVOLVIMENTO 78 relatos, a maior parte dos autores recomenda que se considere um sintoma como presente mesmo quando somente ou os pais ou a criança o reporte.10 A ansiedade patológica não apresenta marcadores qualitativos confiáveis, isto é, não há elementos simples cuja presença ou ausência possa definir se um sintoma é normal ou parte de um transtorno de ansiedade. A diferenciação da ansiedade normal em crianças é feita, portanto, pela intensidade dos sintomas.2 Via de regra, consideram-se anormais sintomas que aconteçam ao menos três a cinco vezes por semana, com intensidade e duração suficientes para influenciar perceptivelmente o comportamento da criança em relação ao esperado para a idade. Ansiedade clinicamente significativa está em geral associada a maior quantidade de sintomas físicos, sobretudo tensão muscular, taquicardia, sudorese, sensação de sufocamento e sono inquieto. A reação normal a uma situação ansiogênica varia com a idade. Crianças mais novas tendem a buscar influenciar o estímulo aversivo, seja enfrentando-o e fugindo, seja protestando sobre sua presença. Já crianças mais velhas e adolescentes percebem a inevitabilidade de alguns estímulos ansiogênicos e um comportamento de aceitação costuma ser desenvolvido. Crianças ansiosas tendem a exibir comportamentos evitativos em relação às mesmas situações, costumam minimizar o contato com as situações temidas, seja se recusando a fazer atividades que possam expô-las à situação, como “não ir à escola porque sua mãe pode ir embora”, ou imprimir grandes esforços para contornar uma ameaça exagerada – “não sobe de elevador, só de escada, porque pode ficar preso sozinho”. Comportamentos de verificação e segurança, como telefonar diversas vezes para os pais para saber se está tudo bem, mesmo no horário da escola, também são comuns. Uma vez determinada a presença de ansiedade clinicamente significativa, o diagnóstico diferencial entre os transtornos de ansiedade pode ser realizado. A presença de mais de um transtorno de ansiedade é muito comum em pacientes com TDAH, portanto não deve ser DESENVOLVIMENTO", "79 surpresa para o examinador que seu paciente preencha critérios para múltiplos diagnósticos específicos ao final da avaliação. 2.2.10 Transtorno de Ansiedade Generalizada O transtorno de ansiedade generalizada (TAG) tem como característica principal a preocupação excessiva, irrealista, não focada em um objeto ou situação específica. Afeta entre 0,5 e 2,8% das crianças e adolescentes na população geral4 e cerca de 12% das crianças com TDAH.12 Os critérios diagnósticos segundo o DSM-5estão listados no Quadro 11.1. QUADRO 1 - 11.1 TRANSTORNO DE ANSIEDADE GENERALIZADA (INCLUI TRANSTORNO DE EXCESSO DE ANSIEDADE DA INFÂNCIA)", "Crianças com TAG têm preocupações mais intensas e persistentes do que outras crianças da mesma idade. Embora o foco principal de preocupação possa variar ao longo do tempo, tende a se concentrar em temas como desempenho escolar, segurança da criança e de parentes próximos, doenças e desastres naturais. Esses relatos são costumeiramente A. Ansiedade e preocupação excessivas (expectativa apreensiva), ocorrendo na maioria dos dias por pelo menos seis meses, com diversos eventos ou atividades (tais como desempenho escolar ou profissional). B. O indivíduo considera difícil controlar a preocupação. C. A ansiedade e a preocupação estão associadas com três (ou mais) dos seguintes seis sintomas (com pelo menos alguns deles presentes na maioria dos dias nos últimos seis meses). Nota: Apenas um item é exigido para crianças. 1. Inquietação ou sensação de estar com os nervos à flor da pele. 2. Fatigabilidade. 3. Dificuldade em concentrar-se ou sensações de “branco” na mente. 4. Irritabilidade. 5. Tensão muscular. 6. Perturbação do sono (dificuldade em conciliar ou manter o sono, ou sono insatisfatório e inquieto). D. A ansiedade, a preocupação ou os sintomas físicos causam sofrimento clinicamente significativo ou prejuízo no funcionamento social, profissional ou em outras áreas importantes da vida do indivíduo. E. A perturbação não se deve aos efeitos fisiológicos de uma substância (p. ex., droga de abuso, medicamento) ou a outra condição médica (p. ex., hipertireoidismo). F. A perturbação não é mais bem explicada por outro transtorno mental (p. ex., ansiedade ou preocupação quanto a ter ataques de pânico no transtorno de pânico, avaliação negativa no transtorno de ansiedade social [fobia social], contaminação ou outras obsessões no transtorno obsessivo-compulsivo, separação das figuras de apego no transtorno de ansiedade de separação, lembranças de eventos traumáticos no transtorno de estresse pós-traumático, ganho de peso na anorexia nervosa, queixas físicas no transtorno de sintomas somáticos, percepção de problemas na aparência no transtorno dismórfico corporal, ter uma doença séria no transtorno de ansiedade de doença ou o conteúdo de crenças delirantes na esquizofrenia ou transtorno delirante) DESENVOLVIMENTO 80 acompanhados de sintomas físicos como palpitações, sudorese, dores inexplicáveis, tensão muscular e sintomas gastrintestinais.13 Independentemente do tema, a incapacidade de controlar a preocupação é característica, e pode ser fonte de maiores dificuldades de atenção, visto que a criança não consegue “desligar” a preocupação para se focar em tarefas habituais. Em algumas situações, esses sintomas de ansiedade podem simular uma resposta insuficiente ao tratamento do TDAH. Embora esse seja o transtorno de ansiedade mais comum na maioria dos levantamentos diagnósticos em pacientes com TDAH, ainda há poucos estudos que avaliam especificamente essa comorbidade. 2.2.11 Transtorno de Ansiedade Social Timidez e vergonha são associadas a comportamentos normais, algumas vezes valorizados na infância. Estudos prospectivos indicam, no entanto, que esses traços podem não ter um curso tão benigno quanto imaginado previamente, ao menos para um subgrupo de crianças. O transtorno de ansiedade social (TAS), também conhecido como fobia social, é caracterizado por um medo excessivo de situações sociais ou de desempenho nas quais a criança possa ser exposta a observação ou humilhação.14 O TAS apresenta uma prevalência pontual de aproximadamente 3% das crianças sem TDAH e cerca de 14% em portadores do transtorno. Tem um pico de incidência aproximadamente aos 15 anos, com prevalências maiores em adolescentes do que em crianças. Contudo, a maior parte dos portadores relata ter os sintomas “desde sempre”, e não é incomum encontrar pacientes mais novos com sintomas subclínicos e até mesmo clinicamente significativos aos 8 ou 9 anos.15 Crianças com TAS apresentam sintomas quase todos os dias, principalmente na escola. As situações mais temidas são normalmente falar com colegas, ler em voz alta na sala de aula, DESENVOLVIMENTO", "81 escrever no quadro negro ou se apresentar em público. Essas situações ou a expectativa delas elicita intensa apreensão, normalmente acompanhada de sintomas físicos de ansiedade e de rubor facial, e leva a evitação e déficits de habilidades sociais. Os critérios diagnósticos para o TAS, segundo o DSM-5, estão listados no Quadro 11.2. QUADRO 2 - 11.2 TRANSTORNO DE ANSIEDADE SOCIAL", "Didaticamente, o TAS pode ser dividido em dois subgrupos. Crianças com ansiedade em múltiplas situações de interação social e desempenho parecem ter características distintas daquelas que apresentam apenas uma situação de medo social (escrever ou falar em público, por exemplo). O TAS generalizado é costumeiramente mais grave, apresenta mais comorbidades com outros transtornos de ansiedade, é mais persistente e provoca maior prejuízo às atividades da vida diária em relação ao TAS restrito.14 A. Medo ou ansiedade acentuados acerca de uma ou mais situações sociais em que o indivíduo é exposto a possível avaliação por outras pessoas. Exemplos incluem interações sociais (p. ex., manter uma conversa, encontrar pessoas que não são familiares), ser observado (p. ex., comendo ou bebendo) e situações de desempenho diante de outros (p. ex., proferir palestras). Nota: Em crianças, a ansiedade deve ocorrer em contextos que envolvem seus pares, e não apenas em interações com adultos. B. O indivíduo teme agir de forma a demonstrar sintomas de ansiedade que serão avaliados negativamente (i.e., será humilhante ou constrangedor; provocará a rejeição ou ofenderá a outros). C. As situações sociais quase sempre provocam medo ou ansiedade. Nota: Em crianças, o medo ou ansiedade pode ser expresso chorando, com ataques de raiva, imobilidade, comportamento de agarrar-se, encolhendo-se ou fracassando em falar em situações sociais. D. As situações sociais são evitadas ou suportadas com intenso medo ou ansiedade. E. O medo ou ansiedade é desproporcional à ameaça real apresentada pela situação social e o contexto sociocultural. F. O medo, ansiedade ou esquiva é persistente, geralmente durando mais de seis meses. G. O medo, ansiedade ou esquiva causa sofrimento clinicamente significativo ou prejuízo no funcionamento social, profissional ou em outras áreas importantes da vida do indivíduo. H. O medo, ansiedade ou esquiva não é consequência dos efeitos fisiológicos de uma substância (p. ex., droga de abuso, medicamento) ou de outra condição médica. I. O medo, ansiedade ou esquiva não é mais bem explicado pelos sintomas de outro transtorno mental, como transtorno de pânico, transtorno dismórfico corporal ou transtorno do espectro autista. J. Se outra condição médica (p. ex., doença de Parkinson, obesidade, desfiguração por queimaduras ou ferimentos) está presente, o medo, ansiedade ou esquiva é claramente não relacionado ou é excessivo. Especificar se: Somente desempenho: Se o medo está restrito à fala ou ao desempenhar em público. DESENVOLVIMENTO DESENVOLVIMENTO", "83 QUADRO 3 - 11.3 TRANSTORNO DE PÂNICO", "Os ataques de pânico na população pediátrica são caracterizados principalmente pelos sintomas somáticos como palpitações, tremores e sudorese. Os sintomas cognitivos – medo de morrer, perder o controle, enlouquecer – tendem a ser menos exuberantes nas crianças do que em populações mais velhas. Os sintomas costumam ter início abrupto, atingindo a maior intensidade em cerca de 10 minutos, diminuindo progressivamente em seguida. É importante lembrar que ataques de pânico isolados não são suficientes para o diagnóstico de TP. O primeiro episódio deve ser espontâneo – ou seja, não deflagrado por um evento estressor claro ou A. Ataques de pânico recorrentes e inesperados. Um ataque de pânico é um surto abrupto de medo intenso ou desconforto intenso que alcança um pico em minutos e durante o qual ocorrem quatro (ou mais) dos seguintes sintomas: Nota: O surto abrupto pode ocorrer a partir de um estado calmo ou de um estado ansioso. 1. Palpitações, coração acelerado, taquicardia. 2. Sudorese. 3. Tremores ou abalos. 4. Sensações de falta de ar ou sufocamento. 5. Sensações de asfixia. 6. Dor ou desconforto torácico. 7. Náusea ou desconforto abdominal. 8. Sensação de tontura, instabilidade, vertigem ou desmaio. 9. Calafrios ou ondas de calor. 10. Parestesias (anestesia ou sensações de formigamento). 11. Desrealização (sensações de irrealidade) ou despersonalização (sensação de estar distanciado de si mesmo). 12. Medo de perder o controle ou “enlouquecer”. 13. Medo de morrer. Nota: Podem ser vistos sintomas específicos da cultura (p. ex., tinido, dor na nuca, cefaleia, gritos ou choro incontrolável). Esses sintomas não devem contar como um dos quatro sintomas exigidos. B. Pelo menos um dos ataques foi seguido de um mês (ou mais) de uma ou de ambas as seguintes características: 1. Apreensão ou preocupação persistente acerca de ataques de pânico adicionais ou sobre suas consequências (p. ex., perder o controle, ter um ataque cardíaco, “enlouquecer”). 2. Uma mudança desadaptativa significativa no comportamento relacionada aos ataques (p. ex., comportamentos que têm por finalidade evitar ter ataques de pânico, como a esquiva de exercícios ou situações desconhecidas). C. A perturbação não é consequência dos efeitos psicológicos de uma substância (p. ex., droga de abuso, medicamento) ou de outra condição médica (p. ex., hipertireoidismo, doenças cardiopulmonares). D. A perturbação não é mais bem explicada por outro transtorno mental (p. ex., os ataques de pânico não ocorrem apenas em resposta a situações sociais temidas, como no transtorno de ansiedade social; em resposta a objetos ou situações fóbicas circunscritas, como na fobia específica; em resposta a obsessões, como no transtorno obsessivo-compulsivo; em resposta à evocação de eventos traumáticos, como no transtorno de estresse pós-traumático; ou em resposta à separação de figuras de apego, como no transtorno de ansiedade de separação). DESENVOLVIMENTO 84 relacionado a outro transtorno de ansiedade –, seguido de um período de ao menos um mês com ataques recorrentes, ou preocupação com novos ataques.16 2.2.13 Transtorno Obsessivo-compulsivo O transtorno obsessivo-compulsivo (TOC) é caracterizado pela presença de obsessões e/ou compulsões de maneira persistente e que causem prejuízo clinicamente significativo (Quadro 11.4). A prevalência de TOC é estimada entre 2 e 4% da população pediátrica, e não parece estar presente especificamente em pacientes com TDAH. Entre crianças com TOC, no entanto, notavelmente mais da metade preenche critérios para TDAH. Embora as origens dessa relação assimétrica sejam ainda desconhecidas, estudos de segregação familiar que compararam famílias de probandos com TDAH ou TOC isoladamente com pacientes com TDAH e TOC em comorbidade revelaram que a prevalência de TDAH está aumentada em familiares de pacientes com TDAH, a de TOC, em familiares de pacientes com TOC, mas a comorbidade TDAH e TOC só está aumentada apenas nos parentes com TDAH e TOC. Isso indica que existe um fator genético para a comorbidade TDAH e TOC que é distinto do risco para os transtornos em separado.10 Obsessões são pensamentos, imagens ou impulsos que se intrometem no curso normal das ideias de maneira desagradável ou inapropriada, e causam incômodo proeminente. Compulsões são comportamentos (lavagem das mãos, entrar e sair de uma porta, endireitar objetos) ou atos mentais (contagem, rezas, repetição de frases) que são realizados como forma de aliviar uma obsessão e/ou de acordo com regras rígidas. Pacientes mais jovens com TOC podem ainda relatar “uma voz interior” que dirige a realização dos rituais, apresentam mais dúvidas e indecisão em matérias triviais, são mais lentas em tarefas diárias e ficam extremamente aliviadas com a realização das compulsões.18 Os temas ou dimensões mais comuns no TOC envolvem simetria, com compulsões de contagem, ordenamento e repetição; DESENVOLVIMENTO", "85 pensamentos tabus, com obsessões de agressão, religião ou conteúdo sexual; compulsões de checagem; contaminação, com compulsões de lavagem; e colecionismo patológico. QUADRO 4 - QUADRO 11.4 TRANSTORNO OBSESSIVO-COMPULSIVO", "Adultos com TOC apresentam graus variados de consciência de morbidade, mas a maioria é consciente que seus sintomas são inapropriados ou “absurdos”", " Em crianças, essa consciência está comumente ausente, e os pacientes podem realmente acreditar que “se não A", " Presença de obsessões, compulsões ou ambas: Obsessões são definidas por (1) e (2): 1", " Pensamentos, impulsos ou imagens recorrentes e persistentes que, em algum momento durante a perturbação, são experimentados como intrusivos e indesejados e que, na maioria dos indivíduos, causam acentuada ansiedade ou sofrimento", " 2", " O indivíduo tenta ignorar ou suprimir tais pensamentos, impulsos ou imagens ou neutralizá-los com algum outro pensamento ou ação", " As compulsões são definidas por (1) e (2): 1", " Comportamentos repetitivos (p", " ex", ", lavar as mãos, organizar, verificar) ou atos mentais (p", " ex", ", orar, contar ou repetir palavras em silêncio) que o indivíduo se sente compelido a executar em resposta a uma obsessão ou de acordo com regras que devem ser rigidamente aplicadas", " 2", " Os comportamentos ou os atos mentais visam prevenir ou reduzir a ansiedade ou o sofrimento ou evitar algum evento ou situação temida; entretanto, esses comportamentos ou atos mentais não têm uma conexão realista com o que visam neutralizar ou evitar ou são claramente excessivos", " Nota: Crianças pequenas podem não ser capazes de enunciar os objetivos desses comportamentos ou atos mentais", " B", " As obsessões ou compulsões tomam tempo (p", " ex", ", tomam mais de uma hora por dia) ou causam sofrimento clinicamente significativo ou prejuízo no funcionamento social, profissional ou em outras áreas importantes da vida do indivíduo", " C", " Os sintomas obsessivo-compulsivos não se devem aos efeitos fisiológicos de uma substância (p", " ex", ", droga de abuso, medicamento) ou a outra condição médica", " D", " A perturbação não é mais bem explicada pelos sintomas de outro transtorno mental (p", " ex", ", preocupações excessivas, como no transtorno de ansiedade generalizada; preocupação com a aparência, como no transtorno dismórfico corporal; dificuldade de descartar ou se desfazer de pertences, como no transtorno de acumulação; arrancar os cabelos, como na tricotilomania [transtorno de arrancar o cabelo]; beliscar a pele, como no transtorno de escoriação [skin-picking]; estereotipias, como no transtorno de movimento estereotipado; comportamento alimentar ritualizado, como nos transtornos alimentares; preocupação com substâncias ou jogo, como nos transtornos relacionados a substâncias e transtornos aditivos; preocupação com ter uma doença, como no transtorno de ansiedade de doença; impulsos ou fantasias sexuais, como nos transtornos parafílicos; impulsos, como nos transtornos disruptivos, do controle de impulsos e da conduta; ruminações de culpa, como no transtorno depressivo maior; inserção de pensamento ou preocupações delirantes, como nos transtornos do espectro da esquizofrenia e outros transtornos psicóticos; ou padrões repetitivos de comportamento, como no transtorno do espectro autista)", " Especificar se: Com insight bom ou razoável: O indivíduo reconhece que as crenças do transtorno obsessivo-compulsivo são definitiva ou provavelmente não verdadeiras ou que podem ou não ser verdadeiras", " Com insight pobre: O indivíduo acredita que as crenças do transtorno obsessivo-compulsivo são provavelmente verdadeiras", " Com insight ausente/crenças delirantes: O indivíduo está completamente convencido de que as crenças do transtorno obsessivo-compulsivo são verdadeiras", " Especificar se: Relacionado a tique: O indivíduo tem história atual ou passada de um transtorno de tique", " DESENVOLVIMENTO 86 andar em múltiplos de sete, minha mãe vai morrer”", " A presença de compulsão associada e o conteúdo típico do pensamento mágico são característicos, e não devem ser confundidos com sintomas psicóticos", " O TOC está frequentemente associado a outros transtornos do espectro obsessivo-compulsivo, e os transtornos de tiques e a síndrome de Tourette são de especial interesse para o tratamento dos pacientes com TDAH", " Cerca de 20% dos pacientes com TDAH desenvolvem tiques em algum momento do desenvolvimento, e os sintomas motores costumam suceder o TDAH em dois a três anos", " Diversos autores observaram o surgimento de tiques associados ao uso de psicoestimulantes para o tratamento do TDAH", " Embora esses relatos tenham impactado a prática clínica a ponto de advertências serem incorporadas nas bulas dos medicamentos, uma metanálise recente não confirma essa associação", "19 O TDAH costuma ser a maior fonte de prejuízo nas crianças com TDAH e tiques, e, dada a evidência atual, esses pacientes não devem ser privados do tratamento mais eficaz para seus sintomas", " Alguns autores descrevem um grupo específico de crianças com TDAH e TOC, que apresentam características clínicas peculiares", " São com mais frequência do sexo masculino, e apresentam predominantemente compulsões de contagem e organização, com transtornos de tiques ou síndrome de Tourette concomitantes", "10 2", "2", "14 Transtorno de Estresse Pós-traumático A característica fundamental do transtorno de estresse pós-traumático (TEPT) é a exposição a um estressor traumático extremo, que é caracterizado pelo sofrimento ou testemunho de um evento que envolva morte ou ferimento grave (ou a ameaça real destes)", " Eventos traumáticos são relativamente comuns ao longo da vida", " Estima-se que, nos Estados Unidos, ao menos 25% das pessoas tenham sido expostas a um evento estressor grave antes dos 16 anos, e que até 43% das crianças tenham sofrido um trauma em algum momento", "20 As DESENVOLVIMENTO 87 circunstâncias mais comumente envolvidas são violência e abuso doméstico, acidentes e doenças graves, e cerca de 10% das crianças desenvolvem sintomas persistentes após a experiência traumática", " O diagnóstico, segundo os critérios do DSM-5 (Quadro 11", "5), além da exposição ao trauma, requer que sintomas de revivescência, esquiva, entorpecimento emocional e hiperatividade autonômica estejam presentes após ao menos um mês do evento traumático", " O manual oferece também, para crianças com menos de 6 anos, critérios específicos que consideram as particularidades de desenvolvimento e a validade maior de sintomas comportamentais neste grupo", " QUADRO 5 - 11", "5 TRANSTORNO DE ESTRESSE PÓS-TRAUMÁTICO TRANSTORNO DE ESTRESSE PÓS-TRAUMÁTICO Nota: Os critérios a seguir aplicam-se a adultos, adolescentes e crianças acima de 6 anos de idade", " Para crianças com menos de 6 anos, consulte os critérios correspondentes a seguir", " A", " Exposição a episódio concreto ou ameaça de morte, lesão grave ou violência sexual em uma (ou mais) das seguintes formas: 1", " Vivenciar diretamente o evento traumático", " 2", " Testemunhar pessoalmente o evento traumático ocorrido com outras pessoas", " 3", " Saber que o evento traumático ocorreu com familiar ou amigo próximo", " Nos casos de episódio concreto ou ameaça de morte envolvendo um familiar ou amigo, é preciso que o evento tenha sido violento ou acidental", " 4", " Ser exposto de forma repetida ou extrema a detalhes aversivos do evento traumático (p", " ex", ", socorristas que recolhem restos de corpos humanos; policiais repetidamente expostos a detalhes de abuso infantil)", " Nota: O Critério A4 não se aplica à exposição por meio de mídia eletrônica, televisão, filmes ou fotografias, a menos que tal exposição esteja relacionada ao trabalho", " B", " Presença de um (ou mais) dos seguintes sintomas intrusivos associados ao evento traumático, começando depois de sua ocorrência: 1", " Lembranças intrusivas angustiantes, recorrentes e involuntárias do evento traumático", " Nota: Em crianças acima de 6 anos de idade, pode ocorrer brincadeira repetitiva na qual temas ou aspectos do evento traumático são expressos", " 2", " Sonhos angustiantes recorrentes nos quais o conteúdo e/ou o sentimento do sonho estão relacionados ao evento traumático", " Nota: Em crianças, pode haver pesadelos sem conteúdo identificável", " 3", " Reações dissociativas (p", " ex", ", flashbacks) nas quais o indivíduo sente ou age como se o evento traumático estivesse ocorrendo novamente", " (Essas reações podem ocorrer em um continuum, com a expressão mais extrema na forma de uma perda completa de percepção do ambiente ao redor", ") Nota: Em crianças, a reencenação específica do trauma pode ocorrer na brincadeira", " 4", " Sofrimento psicológico intenso ou prolongado ante a exposição a sinais internos ou externos que simbolizem ou se assemelhem a algum aspecto do evento traumático", " 5", " Reações fisiológicas intensas a sinais internos ou externos que simbolizem ou se assemelhem a algum aspecto do evento traumático", " DESENVOLVIMENTO C", " Evitação persistente de estímulos associados ao evento traumático, começando após a ocorrência do evento, conforme evidenciado por um ou ambos dos seguintes aspectos: 1", " Evitação ou esforços para evitar recordações, pensamentos ou sentimentos angustiantes acerca de ou associados de perto ao evento traumático", " 2", " Evitação ou esforços para evitar lembranças externas (pessoas, lugares, conversas, atividades, objetos, situações) que despertem recordações, pensamentos ou sentimentos angustiantes acerca de ou associados de perto ao evento traumático", " D", " Alterações negativas em cognições e no humor associadas ao evento traumático começando ou piorando depois da ocorrência de tal evento, conforme evidenciado por dois (ou mais) dos seguintes aspectos: 1", " Incapacidade de recordar algum aspecto importante do evento traumático (geralmente devido a amnésia dissociativa, e não a outros fatores, como traumatismo craniano, álcool ou drogas)", " 2", " Crenças ou expectativas negativas persistentes e exageradas a respeito de si mesmo, dos outros e do mundo (p", " ex", ", “Sou mau”, “Não se deve confiar em ninguém”, “O mundo é perigoso”, “Todo o meu sistema nervoso está arruinado para sempre”)", " 3", " Cognições distorcidas persistentes a respeito da causa ou das consequências do evento traumático que levam o indivíduo a culpar a si mesmo ou os outros", " 4", " Estado emocional negativo persistente (p", " ex", ", medo, pavor, raiva, culpa ou vergonha)", " 5", " Interesse ou participação bastante diminuída em atividades significativas", " 6", " Sentimentos de distanciamento e alienação em relação aos outros", " 7", " Incapacidade persistente de sentir emoções positivas (p", " ex", ", incapacidade de vivenciar sentimentos de felicidade, satisfação ou amor)", " E", " Alterações marcantes na excitação e na reatividade associadas ao evento traumático, começando ou piorando após o evento, conforme evidenciado por dois (ou mais) dos seguintes aspectos: 1", " Comportamento irritadiço e surtos de raiva (com pouca ou nenhuma provocação) geralmente expressos sob a forma de agressão verbal ou física em relação a pessoas e objetos", " 2", " Comportamento imprudente ou autodestrutivo", " 3", " Hipervigilância", " 4", " Resposta de sobressalto exagerada", " 5", " Problemas de concentração", " 6", " Perturbação do sono (p", " ex", ", dificuldade para iniciar ou manter o sono, ou sono agitado)", " F", " A perturbação (Critérios B, C, D e E) dura mais de um mês", " G", " A perturbação causa sofrimento clinicamente significativo e prejuízo social, profissional ou em outras áreas importantes da vida do indivíduo", " H", " A perturbação não se deve aos efeitos fisiológicos de uma substância (p", " ex", ", medicamento, álcool) ou a outra condição médica", " Determinar o subtipo: Com sintomas dissociativos: Os sintomas do indivíduo satisfazem os critérios de transtorno de estresse pós-traumático, e, além disso, em resposta ao estressor, o indivíduo tem sintomas persistentes ou recorrentes de: 1", " Despersonalização: Experiências persistentes ou recorrentes de sentir-se separado e como se fosse um observador externo dos processos mentais ou do corpo (p", " ex", ", sensação de estar em um sonho; sensação de irrealidade de si mesmo ou do corpo ou como se estivesse em câmera lenta)", " 2", " Desrealização: Experiências persistentes ou recorrentes de irrealidade do ambiente ao redor (p", " ex", ", o mundo ao redor do indivíduo é sentido como irreal, onírico, distante ou distorcido)", " Nota: Para usar esse subtipo, os sintomas dissociativos não podem ser atribuíveis aos efeitos fisiológicos de uma substância (p", " ex", ", apagões, comportamento durante intoxicação alcoólica) ou a outra condição médica (p", " ex", ", convulsões parciais complexas)", " Especificar se: Com expressão tardia: Se todos os critérios diagnósticos não forem atendidos até pelo menos seis meses depois do evento (embora a manifestação inicial e a expressão de alguns sintomas possam ser imediatas)", " DESENVOLVIMENTO Transtorno de estresse pós-traumático em crianças de 6 anos ou menos A", " Em crianças de 6 anos ou menos, exposição a episódio concreto ou ameaça de morte, lesão grave ou violência sexual em uma (ou mais) das seguintes formas: 1", " Vivenciar diretamente o evento traumático", " 2", " Testemunhar pessoalmente o evento ocorrido com outras pessoas, especialmente cuidadores primários", " Nota: O testemunho não inclui eventos vistos apenas em mídia eletrônica, televisão, filmes ou fotografias", " 3", " Saber que o evento traumático ocorreu com pai/mãe ou cuidador", " B", " Presença de um (ou mais) dos seguintes sintomas intrusivos associados ao evento traumático, começando depois de sua ocorrência: 1", " Lembranças intrusivas angustiantes, recorrentes e involuntárias do evento traumático", " Nota: Lembranças espontâneas e intrusivas podem não parecer necessariamente angustiantes e podem ser expressas como reencenação em brincadeiras", " 2", " Sonhos angustiantes recorrentes nos quais o conteúdo e/ou a emoção do sonho estão relacionados ao evento traumático", " Nota: Pode não ser possível determinar que o conteúdo assustador está relacionado ao evento traumático", " 3", " Reações dissociativas (p", " ex", ", flashbacks) nas quais a criança sente ou age como se o evento traumático estivesse acontecendo novamente", " (Essas reações podem ocorrer em um continuum, com a expressão mais extrema manifestada como uma perda completa da percepção do ambiente ao redor", ") Essa reencenação específica do trauma pode ocorrer na brincadeira", " 4", " Sofrimento psicológico intenso ou prolongado ante a exposição a sinais internos ou externos que simbolizem ou se assemelhem a algum aspecto do evento traumático", " 5", " Reações fisiológicas intensas a lembranças do evento traumático", " C", " Um (ou mais) dos seguintes sintomas, representando evitação persistente de estímulos associados ao evento traumático ou alterações negativas em cognições e no humor associadas ao evento traumático, deve estar presente, começando depois do evento ou piorando após sua ocorrência", " Evitação persistente de estímulos 1", " Evitação ou esforços para evitar atividades, lugares ou lembranças físicas que despertem recordações do evento traumático", " 2", " Evitação ou esforços para evitar pessoas, conversas ou situações interpessoais que despertem recordações do evento traumático", " Alterações negativas em cognições 3", " Frequência substancialmente maior de estados emocionais negativos (p", " ex", ", medo, culpa, tristeza, vergonha, confusão)", " 4", " Interesse ou participação bastante diminuídos em atividades significativas, incluindo redução do brincar", " 5", " Comportamento socialmente retraído", " 6", " Redução persistente na expressão de emoções positivas", " D", " Alterações na excitação e na reatividade associadas ao evento traumático, começando ou piorando depois de sua ocorrência, conforme evidenciado por dois (ou mais) dos seguintes aspectos: 1", " Comportamento irritadiço ou surtos de raiva (com pouca ou nenhuma provocação) geralmente manifestados como agressão verbal ou física em relação a pessoas ou objetos (incluindo acessos de raiva extremos)", " 2", " Hipervigilância", " 3", " Respostas de sobressalto exageradas", " 4", " Problemas de concentração", " 5", " Perturbação do sono (p", " ex", ", dificuldade em iniciar ou manter o sono, ou sono agitado)", " E", " A perturbação dura mais de um mês", " F", " A perturbação causa sofrimento clinicamente significativo ou prejuízo nas relações com pais, irmãos, amigos ou outros cuidadores ou no comportamento na escola", " G", " A perturbação não se deve aos efeitos fisiológicos de uma substância (p", " ex", ", medicamento ou álcool) ou a outra condição médica", " Determinar o subtipo: Com sintomas dissociativos: Os sintomas do indivíduo satisfazem os critérios para transtorno de estresse pós-traumático, e o indivíduo sofre sintomas persistentes ou recorrentes de: 1", " Despersonalização: Experiências persistentes ou recorrentes de sentir-se separado e como se fosse um observador externo dos processos mentais ou do corpo (p", " ex", ", sensação de estar em um sonho; sensação de irrealidade de si mesmo ou do corpo ou como se estivesse em câmera lenta)", " 2", " Desrealização: Experiências persistentes ou recorrentes de irrealidade do ambiente ao redor (p", " ex", ", o mundo ao redor do indivíduo é sentido como irreal, onírico, distante ou distorcido)", " Nota: Para usar esse subtipo, é preciso que os sintomas dissociativos não sejam atribuíveis aos efeitos fisiológicos de uma substância (p", " ex", ", apagões) ou a outra condição médica (p", " ex", ", convulsões parciais complexas)", " Especificar se: Com expressão tardia: Se todos os critérios diagnósticos não forem atendidos até pelo menos seis meses depois do evento (embora a manifestação inicial e a expressão de alguns sintomas possam ser imediatas)", " DESENVOLVIMENTO DESENVOLVIMENTO DESENVOLVIMENTO 92 Recomenda-se iniciar o tratamento farmacológico para o TDAH com ansiedade comórbida com um psicoestimulante, como habitual, e avaliar a resposta para ambos os transtornos", " Em caso de resposta insuficiente da ansiedade, o tratamento com TCC deve ser iniciado, e, quando este se mostrar ineficaz ou indisponível, a adição de um inibidor seletivo deve ser considerada", " Tanto a psicoterapia de orientação cognitivo-comportamental quanto os tratamentos farmacológicos costumam ser direcionados aos transtornos de ansiedade de forma geral, sem a separação de diagnósticos específicos", " Presume-se que transtornos como TAG, TP e TAS tenham etiologias superpostas, e sabe-se que apresentam respostas semelhantes a intervenções semelhantes", " O tratamento do TOC merece ser considerado separadamente, visto que apresenta particularidades importantes", " Nesses casos, o uso de doses mais altas de inibidores seletivos de recaptação de serotonina deve ser considerado regra", " O tratamento psicoterápico deve ser focado nos procedimentos de exposição e prevenção de resposta, com as intervenções cognitivas em secundário, e sabendo que não há evidências da eficácia das técnicas de relaxamento", " 2", "2", "16 Referências 1", " Stein DJ, Hollander E, Rothbaum BO", " Textbook of Anxiety Disorders, Second Edition", " American Psychiatric Pub; 2009", " 1 p", " 2", " Schniering CA, Hudson JL, Rapee RM", " Issues in the diagnosis and assessment of anxiety disorders in children and adolescents", " Clinical Psychology Review", " 2000 Jun;20(4):453–78", " 3", " Mash EJ, Barkley RA", " Child Psychopathology", " Second Edition", " Guilford Press; 2013", " 1 p", " 4", " Rapee RM, Schniering CA, Hudson JL", " Anxiety disorders during childhood and adolescence: origins and treatment", " Annu Rev Clin Psychol", " 2009;5:311–41", " DESENVOLVIMENTO 93 5", " Pliszka SR", " Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview", " J Clin Psychiatry", " 1998;59 Suppl 7:50–8", " 6", " Souza I, Pinheiro MA, Denardin D, Mattos P, Rohde LA", " Attention-deficit/hyperactivity disorder and comorbidity in Brazil: comparisons between two referred samples", " European Child & Adolescent Psychiatry", " 2004 Aug;13(4):243–8", " 7", " Spencer T, Biederman J, Wilens T", " Attention-deficit/hyperactivity disorder and comorbidity", " Pediatr Clin North Am", " 1999 Oct;46(5):915–27–vii", " 8", " Pliszka SR, Carlson CL, Swanson JM", " ADHD with Comorbid Disorders", " The Guilford Press; 2001", " 1 p", " 9", " Schatz DB, Rostain AL", " ADHD with comorbid anxiety: a review of the current literature", " Journal of Attention Disorders", " 2006 Nov;10(2):141–9", " 10", " Pliszka SR", " Treating ADHD and Comorbid Disorders", " Guilford Press; 2011", " 1 p", " 11", " Lyneham HJ, Rapee RM", " Evaluation and treatment of anxiety disorders in the general pediatric population: a clinician's guide", " Child and Adolescent Psychiatric Clinics of North America", " 2005 Oct;14(4):845–61–x", " 12", " Souza I, Pinheiro MA, Mattos P", " [Anxiety disorders in an attention-deficit/hyperactivity disorder clinical sample]", " Arq Neuropsiquiatr", " 2005 Jun;63(2B):407–9", " 13", " Keeton CP, Kolos AC, Walkup JT", " Pediatric generalized anxiety disorder: epidemiology, diagnosis, and management", " Paediatr Drugs", " 2009;11(3):171–83", " 14", " Chavira DA, Stein MB", " Childhood social anxiety disorder: from understanding to treatment", " Child and Adolescent Psychiatric Clinics of North America", " 2005 Oct;14(4):797–818–ix", " 15", " Kashdan TB, Herbert JD", " Social anxiety disorder in childhood and adolescence: current status and future directions", " Clin Child Fam Psychol Rev", " 2001 Mar;4(1):37–61", " 16", " Suveg C, Aschenbrand SG, Kendall PC", " Separation anxiety disorder, panic disorder, and school refusal", " Child and Adolescent Psychiatric Clinics of North America", " 2005 Oct;14(4):773–95–ix", " 17", " Kessler R", " The Prevalence and Correlates of Adult ADHD in the United States: Results From the National Comorbidity Survey Replication", " Am J Psychiatry", " 2006 Apr 1;163(4):716", " 18", " Boileau B", " A review of obsessive-compulsive disorder in children and adolescents", " Dialogues in Clinical Neuroscience", " Les Laboratoires Servier; 2011 Dec 1;13(4):401", " 19", " Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF", " Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders", " Journal of the American Academy of Child & Adolescent Psychiatry", " 2009 Sep;48(9):884–93", " 20", " De Bellis MD, Van Dillen T", " Childhood post-traumatic stress disorder: an overview", " DESENVOLVIMENTO 94 Child and Adolescent Psychiatric Clinics of North America", " 2005 Oct;14(4):745–72–ix", " 21", " March JS, Swanson JM, Arnold LE, Hoza B", " Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA)", " Journal of abnormal …", " 2000", " 22", " Sumner C, Sher L, Sutton V, Bakken R, Paczkowski M, Trzepacz P, et al", " Atomoxetine Treatment For Pediatric Patients With Adhd And Comorbid Anxiety", " Neuropediatrics", " 2006 May 18;37(S 1):TP74", " 23", " Ipser JC, Stein DJ, Hawkridge S, Hoppe L", " Pharmacotherapy for anxiety disorders in children and adolescents", " Cochrane Database Syst Rev", " 2009;(3):CD005170", " 24", " Abikoff H, McGough J, Vitiello B, McCracken J, Davies M, Walkup J, et al", " Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders", " Journal of the American Academy of Child & Adolescent Psychiatry", " 2005 May;44(5):418–27", " DESENVOLVIMENTO 95 2", "3 ESTUDO 4 – VARIABILIDADE DA FREQUÊNCIA CARDÍACA: UM BIOMARCADOR DE RESPOSTA SELETIVA A INTERVENÇÕES BASEADAS EM MINDFULNESS VERSUS FLUOXETINA NO TRANSTORNO DE ANSIEDADE GENERALIZADA Heart rate variability: a biomarker of selective response to mindfulness-based treatment versus fluoxetine in Generalized Anxiety Disorder", " Rafael Ferreira-Garcia, MD1; Marianna de Abreu Costa, MD4* Francine Gonçalves, MSci4, Roberto Guedes de Nonohay, PhD Antonio Egídio Nardi, MD PhD1 Rafael Christophe da Rocha Freire, MD, PhD1,3 Gisele Gus Manfro, MD, Ph", "D2 1 - Instituto de Psiquiatria - Universidade Federal do Rio de Janeiro 2 - Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil 3 - Department of Psychiatry, School of Medicine, Queen's University", " 4 - Graduate Program in Psychiatry and Behavioral Sciences, Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS) * these authors contributed equally to the work Running Head: HRV predicts treatment response to MBIs Correspondence and reprints: Rafael Ferreira-Garcia Instituto de Psiquiatria - UFRJ Av", " Venceslau Brás, 71 Rio de Janeiro –RJ CEP: 22290-140 Email: rafaelfg@ipub", "ufrj", "br Keywords: Generalized Anxiety Disorder; Pharmacotherapy; Treatment Response; Mindfulness; Predictor; Moderator Manuscrito em preparação DESENVOLVIMENTO 96 2", "3", "1 Abstract Background: Mindfulness Based Interventions (MBIs) are effective for some, but not all patients with anxiety disorders", " Several studies have looked for predictors and moderators of treatment response in patients with generalized anxiety disorder (GAD), but clinical features have not been consistently able to differentiate which patients are more likely to respond to a specific intervention", " In this study, we tested heart rate variability as a moderator of treatment response to an MBI versus pharmacotherapy", " Methods: Seventy-seven patients with GAD, randomized to pharmacological treatment with fluoxetine or Body-in-Mind Training (an MBI focused on the attention to bodily movement) were included in this study", " HRV data were extracted from baseline pulse wave recordings and was used to predict treatment response as measured by the Hamilton anxiety rating scale at 0, 5, and 8 weeks", " Results: Higher baseline normalized high frequency indexes (HF(nu)) moderated the relationship between treatment group and treatment response (estimate = 4", "27 95%CI [ 1", "19, 8", "19])", " Patient with low HF(nu) had lower depression with fluoxetine treatment, when compared MBI treatment (estimate = -10", "29, 95% CI [ -17", "59, -2", "99,]), while no differences were found between groups in patients with high HF(nu) scores (estimate = -1", "85 CI95%[-9", "21, 5", "52])", " Limitations: The relatively small sample size is reflected in wider uncertainty of effect sizes", " The specificity of the treatment groups limits the generalizability of the finding for other MBIs and pharmacological interventions", " DESENVOLVIMENTO 97 Conclusions: HRV was able to identify a subgroup for which MBI was less effective than pharmacotherapy and is a promising candidate as a selective biomarker for treatment response between an MBI and fluoxetine", "", "DESENVOLVIMENTO 98 2", "3", "2 Introduction Generalized Anxiety Disorder (GAD) is a chronic, debilitating mental disorder mainly characterized by persistent symptoms of excessive and uncontrollable worry", " It is the most common anxiety disorder in primary care settings, with a lifetime prevalence of approximately 3", "7% globally (Ruscio et al", ", 2017)", " Luckily, GAD is a highly treatable condition, for which there is a large number of evidence-based treatment options, including pharmacologic, and nonpharmacologic interventions", " Even with the plurality of effective treatment options available for GAD, 35 to 55% of patients do not respond to the first intervention, many of whom will eventually respond to a different drug, therapy or combination of treatments (Bereza et al", ", 2012)", " While the primary sources of information on the choice of initial treatment are comparative effectiveness studies, these do not usually consider patient-specific factors that could inform clinicians on what specific patient is more likely to respond to one intervention over the other", " The identification of such factors may help personalize treatment choices and increase treatment response to the first intervention (Ferreira-Garcia et al", ", 2017)", " Although drug treatment with selective serotonin reuptake inhibitors (SSRIs) and traditional cognitive behavioral therapy remain the first-line treatment options (Baldwin et al", ", 2012), mindfulness-based interventions (MBI) are rapidly gaining mainstream acceptance in the treatment of generalized anxiety disorder, and other anxiety disorders", " Though comparisons with traditional treatments are rare, MBIs are regarded as a reasonable, low-stigma alternative to conventional forms of psychotherapy or pharmacotherapy for selected patients with GAD (de Abreu Costa et al", ", 2019; Hofmann et al", ", 2010; Wong et al", ", 2016)", " Nevertheless, treatment response rates are not as consistent with MBIs as with traditional cognitive-behavioral therapy or pharmacotherapy (Costa et al", ", 2019; de Abreu Costa et al", ", 2019; Hoge et al", ", 2013), and DESENVOLVIMENTO 99 while some patients seem to do better than others with MBIs, we still do not know how to predict who will eventually respond", " Several studies have looked for predictors and moderators of treatment response in GAD patients, but, to our knowledge, no clinical feature that could be systematically replicated was able to help in the initial treatment choice, neither between psychotherapy and pharmacotherapy, nor between specific drugs or psychotherapy techniques, as a number of systematic reviews have pointed out (Ferreira-Garcia et al", ", 2017; Schneider et al", ", 2015)", " The integration of biomarkers in prognostic models may hold better promise for anxious patients", " Genetic polymorphisms and neuroimaging indexes have already been shown to predict treatment response in GAD and other anxiety disorders (Lueken et al", ", 2016), but costs and availability are still a limiting factor for their extensive use in clinical practice", " Heart rate variability (HRV) is the complex oscillation of heart periods over time, that can be measured by extensively available electrocardiography or pulse monitors from heart period samples as short as 2 minutes", " HRV has been used extensively in research to measure regulated emotional response, as reflected by the differential effects of sympathetic and vagal control, both in resting and task conditions (Appelhans and Luecken, 2006)", " More specifically, High frequency (HF) oscillations are thought to correlate with vagal-mediated heart rate modulation, while low frequency (LF) power is correlated with a combination of vagal and sympathetic influences", " Relative indexes like the LF/HF ratio and HF(nu) are thought to reflect the relative balance of sympathetic and vagal influences in HRV (Quintana et al", ", 2016)", " Reductions in vagal-mediated HRV are thought to reflect a tendency to maladaptive cardiac autonomic response to negative emotions, which are inherent features to anxiety and depressive disorders (Quintana et al", ", 2016)", " HRV seems to be specifically correlated with worrying symptoms across all diagnoses (Chalmers et al", ", 2016) and is predictably decreased in GAD patients (Chalmers et al", ", 2014)", " DESENVOLVIMENTO 100 MBIs as a group are characterized by interventions that foster increased attention towards present experiences, with an attitude of acceptance, curiosity, and openness", " It is thought to improve emotional regulation by targeting the acceptance of emotional experience and executive control of emotions (Teper et al", ", 2013)", " Mindfulness meditation training has been shown to shift the HRV autonomic balance toward a state of predominant vagal control, both in resting and during meditation conditions, reflecting the improvement in overall emotional regulation in both healthy and clinical populations (Delgado et al", ", 2010; Wu and Lo, 2008)", " Lower vagal-mediated HRV was associated with better response to acceptance and commitment therapy (an MBI) and cognitive behavioral therapy, although it was unable to differentiate both groups (Davies et al", ", 2015)", " To our knowledge, no study has tested HRV as a predictor of treatment response in GAD patients (Lueken et al", ", 2016)", " In this article, we analyzed data from a randomized controlled trial, examining the utility of an index of sympathetic/vagal balance as a differential predictor of treatment response between pharmacotherapy with fluoxetine and mindfulness-based therapy for patients with GAD", " DESENVOLVIMENTO 101 2", "3", "3 Materials and Methods This study report results from a large single-blinded randomized control trial comparing a mindfulness-based intervention – Body in Mind Training (BMT) (Russell, 2011), fluoxetine, and a quality of life active comparison group in adults with GAD (Costa et al", ", 2019)", " This study was approved by the Ethics Committee of Hospital de Clínicas de Porto Alegre (20160301)", " All patients provided written informed consent", " Patients were included if they screened positive for GAD using the Brazilian version of the GAD-7 questionnaire (Spitzer et al", ", 2006), had GAD as their primary diagnosis as assessed by the Mini International Neuropsychiatric Interview (M", "I", "N", "I", "), Brazilian Portuguese version (Amorim, 2000), and were not in current treatment for an anxiety disorder", " Patients were excluded if they had a lifetime history of bipolar disorder or psychotic disorder; substance use disorder or suicidal ideation in the last six months; current eating, antisocial personality disorder, or score in the Hamilton Depression Rating Scale (HAMD) (Carneiro et al", ", 2015; Hamilton, 1967) greater than 23", " Patients were also excluded if they had any contraindication to either fluoxetine or BMT treatment", " Baseline assessment also included the Penn-State Worry Questionnaire (PSWQ) (Castillo et al", ", 2010; Meyer et al", ", 1990), that has been shown to correlate with HRV in both the general population and in patients with GAD (Chalmers et al", ", 2016, 2014)", " In order to evaluate moderators between active treatments, in this study we did not include patients in the control condition, restricting our analysis for patients in the two experimental treatment conditions – fluoxetine pharmacotherapy and Body in Mind Training (BMT)", " BMT was delivered as per protocol by an experienced psychologist in 2-hour sessions, for eight weeks", " Briefly, it consists of practices stimulating awareness of bodily sensations, in a self-kind and non-judgmental way, using the proprioceptive feedback of gentle movement of the body to anchor attention resources(Russell, 2011)", " The fluoxetine group was treated for DESENVOLVIMENTO 102 eight weeks with a flexible-dose regimen, in which fluoxetine was started 20mg/day and could be increased by 20mg/ day every three weeks if HAMA scores were higher than 10", " Treatment outcome was defined as the percent improvement in the Hamilton anxiety scale, (HAMA)(Hamilton, 1959) from baseline, and categorical response was defined as 50% or more improvement in the HAMA scale and a Clinical Global Impression – improvement (Busner and Targum, 2007) (CGIi) = 1 or 2, while remission was defined as HAMA scores lower than 7", " HAMA, CGIs and CGIi scores were accessed at weeks 0, 5 and 8, by evaluators blinded to treatment arm", " In this study, we included patients from the fluoxetine and MBT arms, who had useable HRV data from baseline", " HRV data were collected before treatment using a standard procedure", " Subjects were invited to a sound and light attenuated controlled room, where they were instructed to seat in a comfortable position for five minutes", " After this habituation period, 120s of pulse plethysmography (PPG) data were collected using a Shimmer3 GSR with the optical pulse sensor attached to the second and third fingers of the left hand", " Acquisition frequencies were 512Hz for the first three study waves and 65", "5Hz in the last wave", " Data was transferred to the Consensys software and exported for analysis", " PPG signal was inspected for artifacts, filtered using a standard Butterworth filter, and processed using the PhysioNet Cardiovascular Signal Toolbox (Vest et al", ", 2018) in MATLAB R2017b", " Inter-beat intervals that varied by more than 20% from the median five intervals before and after, or that were deemed nonphysiological (IBI > 2s or < 0", "375s) were substituted by cubic interpolation, and Frequency domain data was calculated from the corrected periodograms using the Lomb-Scargle power spectral density estimate", " Frequency domain regions of low frequency (LF) and high frequency (HF) were 0", "04-0", "15 Hz and 0", "15-0", "4 Hz, respectively", " The HF(nu) was calculated and used as an approximate estimate of the vagal predominance in the sympathetic/vagal balance by normalizing the HF values HF(nu)=□(HF/(HF+LF))", " DESENVOLVIMENTO 103 Mixed-effects models were used to analyze longitudinal data, as they provide better estimates, and allow for less strict assumptions about missing data, using the jamovi statistical software for macOS", "(Gallucci, 2019; The jamovi project, 2019) We tested our primary hypothesis that increased relative vagal-mediated HRV, as measured by the HF(nu) index, differentially predicted treatment response between groups by including the interaction between treatment group, HF(nu) and time in the mixed model while controlling by age, sex, education, treatment wave and HAMD scores at baseline", " HAMA score along weeks 0, 5, and 8 were used as the dependent variable, and time was modeled as a polynomial contrast", " We calculated simple effects by using a simple contrast between groups and reported estimated marginal means by assuming fixed values for all covariate parameters for the HAMA as a dependent variable", " Since correction for multiple comparisons in repeated measures mixed models can unnecessarily reduce power, we did not correct for multiple comparisons for simple effects of contrasts, and instead limited our simple effect analyses to the interaction between our moderator variable and group at the 8 weeks endpoint", " Since 50% was the average median value for both groups, we split the variable HF(nu) in > 50% and < 50% categorical groups, to better explore the relationship between group, vagal balance, and treatment response", " Generalized linear models using a logit link function for binary dependent variables were used to predict binary outcomes of non-response / non-remission, controlling by age, sex, education, treatment wave, and HAMD scores at baseline", " DESENVOLVIMENTO 104 2", "3", "4 Results From a total of 164 participants randomized to either, BMT or pharmacotherapy with fluoxetine, seventy-seven patients that had useable baseline HRV data were included in this study", " Patients included did not differ significantly from the whole sample on age, gender, initial severity, group allocation, or dropout rate", " Baseline characteristics of included subjects are summarized in table 1", " Response and remission rates were 29% and 14% in the BMT group vs", " 48% and 21% in the fluoxetine group (NS, Fisher’s exact test)", " No differences between treatment arms were observed for the HF(nu) variable", " In the first mixed model including all covariates and treatment group as independent predictor, the interaction between time and group was significant, (Estimate = -4", "188, ( CI95% -8", "205 to -0", "171, p = 0", "024) A significant simple effect was detected at week 8, indicating that patients on fluoxetine scored 6", "423 points lower in the HAMA when compared to patients treated with BMT, at the end of the study (95%CI[-11", "78, -1,07], p = 0", "019), when all covariates are kept constant", " In order to evaluate HF(nu) global effect as a predictor of treatment response, we added the HF(nu) interaction with time to the model, but this term was not significant (estimate = -9", "95, 95%CI [-21", "47, 1", "58], p<0", "094)", " In the planed analysis a significant interaction between group, baseline HF(nu) and time was present in the mixed-effects model (estimate = 27", "08, 95%CI [4", "65, 49", "50], p<0", "020)", " We performed a median split of the HF(nu) variable to better explore the interaction with time", " Again, the interaction between the binary HF(nu) variable, group and time was significant ( estimate = -11", "57, 95%CI [-19", "30, -3", "83], p<0", "004)", " Simple effect analysis (figure 1) revealed that in the end of the 8 weeks, patients with low HF(nu) at baseline scored on average approximately 10 points lower in the HAMA scale than patients treated with BMT, a large effect, although with a wide confidence interval (estimate = -10", "29, 95%CI [ -17", "59, -2", "99,], p DESENVOLVIMENTO 105 = 0", "006), while no significant difference was observed in patients with high HF(nu) scores (figure 1) (estimate = -1", "85 CI95%[-9", "21, 5", "52], p = 0", "586)", " TABELA 9 - TABLE 1 MBT Fluoxetine p-value n 40 37 Demographics Age (years) 36", "2 ± 13", "9 34", "8±12", "2 n", "s", "a Sex – F (n) 30 29 n", "s", "b Education (n) n", "s", "c < Elementary 2 0 Elementary 0 2 High School 23 18 ≥ College 14 17 Clinical HAMA 28", "6±8", "42 29", "7±8", "93 n", "s", "a GAD-7 16", "2±3", "30 15", "5±2", "67 n", "s", "a HAMD 13", "5±4", "08 15", "5±6", "30 0", "10 a Comorbidities (n) MDD 16 9 n", "s", "b PD 4 5 n", "s", "b Agoraphobia 6 4 n", "s", "b SAD 6 3 n", "s", "b OCD 4 1 n", "s", "b PTSD 4 2 n", "s", "b Heart Rate (bpm) 81", "77±12", "77 85", "58±17", "85 n", "s", "a HRV – median (Range) LF(ms2) 1378 (35113) 1265 (34466) n", "s", "c HF(ms2) 1786 (35977) 1780 (25590) n", "s", "c LF/HF 0", "955 (4", "51) 1", "05 (2", "04) n", "s", "c Baseline characteristics of the HRV sample a Student t test, b Fisher exact test, c Mann-Withney – U, F = Female, HAMA – Hamilton Anxiety Rating Scale, GAD-7= Generalized Anxiety Disorder 7-item (GAD-7) scale, HAMD = Hamilton Depression Rating Scale", " MDD = major depressive disorder, PD = panic disorder, SAD = social anxiety disorder, OCD = obsessive-compulsive disorder, PTST = post-traumatic stress disorder, HRV = heart rate variability, LF = low frequency power, HF = high frequency power, LF/HF = low frequency/high frequency ratio", " DESENVOLVIMENTO Difference between BMT and fluoxetine treated patients at 8 weeks in HAMA total scores in patients with low (≤ 50%) and high ( > 50%) HF(nu)", " A significant interaction between group and HF(nu) group was also detected in the generalized linear model predicting response as a categoric variable", " (estimate = 4", "27 95%CI [ 1", "19, 8", "19], p = 0", "013)", " In patients with low HF(nu) index, BMT treatment had a much lower probability of response than fluoxetine, (0", "05 [0", "01, 0", "35] vs 0", "57 [0", "25, 0", "84], p = 0", "279) Probability of response was similar between BMT and Fluoxetine groups, in patients with high HF(nu) (0", "54 [0", "21, 0", "84] vs 0", "28 [0", "08, 0", "62], p = 0", "279)", " It is important to notice that the 95%CI was wide in both groups, and a smaller effect cannot be excluded", " A similar model for remission as the dependent variable was able to detect the effect at trend level (estimate = -3", "48 95%CI [ -8", "18, 0", "17] p = 0", "087), but simple effects analysis was not significant", " -20-15-10-50510HF(nu) > 50%HF(nu) ≤ 50% Final HAMA score difference (BMT -Fluoxetine) DESENVOLVIMENTO 107 2", "3", "5 Discussion The HF(nu) index of HRV was a strong moderator of treatment response between BMT and fluoxetine", " Although fluoxetine was overall slightly superior to BMT in this study, for patients with higher scores in the HF(nu) index, mindfulness seemed to be at least as effective as fluoxetine, according to our results", " On the other hand, in patients with the lowest scores in the HF(nu) index, BMT faired much worse yielding almost 10 points higher HAMA scores, at the end of the treatment, when compared with patients treated with fluoxetine", " As a comparison, a HAMA of 16 would be considered of mild severity, while a HAMA of 26 would be indicative of moderate to severe anxiety, a clinically meaningful difference", " In our study, BMT treatment was better tailored for patients who already had better HRV correlate of emotional regulation at baseline, indicating that BMT may require a relatively preserved emotional-sympathetic coupling to exert its therapeutic effects in patients with GAD", " Mindfulness-based meditation has been shown to improve emotional regulation in clinical and non-clinical populations (Hölzel et al", ", 2011), and also to shift the heart rate variability indexes to more vagal-mediated states (Pascoe et al", ", 2017)", " Interestingly, a study by Azam et al", " has shown that mindfulness-based meditation was effective in improving HRV in control subject, but not in pathological perfectionists (Azam et al", ", 2015) indicating that some clinical populations may lack the substrate through which MBIs may exert their effect on HRV measurements", " One can speculate that the baseline lower vagal tonus may be specific for a subgroup of patients who may not have sufficient emotional-visceral coupling for mindfulness to exert its effects on emotional regulatory processes, and could explain why MBIs have been shown to have a consistent and large effect size in reducing non-clinical anxiety in healthy individuals(Khoury et al", ", 2015), but less consistently in individuals with anxiety disorders(de Abreu Costa et al", ", 2019)", " DESENVOLVIMENTO 108 Our results contrast with the results reported by Davies et al", ", in which patients in a group of combined anxiety disorders had a better response with lower values of HF(nu), to both acceptance and commitment and cognitive behavioral therapy", " Several factors may account for the different effect direction", " First, although HRV indexes are thought to be on average lower in patients with anxiety and depressive disorders, on the whole, there seem to be specific differences between anxiety disorders both in resting conditions (Kemp et al", ", 2014) and during emotional regulation tasks", " It would not be surprising, therefore, if the moderation effects were disorders-specific, as it has been the case in studies comparing anxious versus non-anxious depression (Kircanski et al", ", 2019), and panic disorder and depression (Choi et al", ", 2019)", " Secondly, we used 2 minutes recordings versus the 5 minutes reported by Davies et al", " Although the HF index and LF indexes can be equivalently estimated from shorter data, metrics derived from different segment durations are not directly comparable (McNames and Aboy, 2006)", " Finally, although acceptance and commitment therapy and BMT are both MBIs, they hold key differences", " BMT is much more focused in bodily movement awareness, with fewer elements of traditional cognitive-behavioral therapy than acceptance and commitment therapy, and had the specific goal “to develop mindful movement exercises for use by anyone who might struggle to engage with the currently available MBIs” (Russell, 2011)", " BMT can thus be expected to be effective for populations with different baseline characteristics than more traditional MBIs", " Although promising, several limitations must be considered when interpreting the results of this study", " First, we had a small total sample size, due to incomplete availability of baseline HRV, which was mainly caused by insufficient quality PPG signal", " Missing data are therefore expected to be randomly distributed across groups and were not expected to add systematic bias to our sample", " Also, we calculated variability from pulse waves, which can be less precise than HRV in some conditions", " Nevertheless, PPG has been shown to be reasonably equivalent to EEG in resting conditions (Lu et al", ", 2009), and should be equivalent for the DESENVOLVIMENTO 109 metrics we used", " Finally, our results also cannot be extended to make inferences about other MBIs or drug treatments, since the effect was not equivalent to similar studies already reported in the literature", " 2", "3", "6 Conclusion Mindfulness-based therapies are useful for some, but not all patients", " The initial treatment choice for GAD is still guided mostly by clinician experience, potential side effects, and patient preferences", " As important as these elements may be for each patient's prognosis, a consistent marker of selective treatment response would be immensely helpful in guiding initial treatment choice", " We suggest that HRV is a promising candidate as a selective biomarker for treatment response between BMT and fluoxetine", " Larger studies designed explicitly for evaluating HRV as moderator of treatment response are necessary to confirm our results and should compare HRV metrics derived from different heart rate data segment durations and acquisition modalities", " DESENVOLVIMENTO 110 2", "3", "7 References Amorim, P", ", 2000", " Mini International Neuropsychiatric Interview ( MINI ): validação de entrevista breve para diagnóstico de transtornos mentais Mini International Neuropsychiatric Interview ( MINI ): validation of a short structured diagnostic psychiatric interview 22", " Appelhans, B", "M", ", Luecken, L", "J", ", 2006", " Heart rate variability as an index of regulated emotional responding", " Rev", " Gen", " Psychol", " 10, 229–240", " https://doi", "org/10", "1037/1089-2680", "10", "3", "229 Azam, M", "A", ", Katz, J", ", Fashler, S", "R", ", Changoor, T", ", Azargive, S", ", Ritvo, P", ", 2015", " Heart rate variability is enhanced in controls but not maladaptive perfectionists during brief mindfulness meditation following stress-induction: A stratified-randomized trial", " Int", " J", " Psychophysiol", " 98, 27–34", " https://doi", "org/10", "1016/j", "ijpsycho", "2015", "06", "005 Baldwin, D", "S", ", Waldman, S", ", Allgulander, C", ", 2012", " Evidence-based pharmacotherapy of generalized anxiety disorder, in: Essential Evidence-Based Psychopharmacology, Second Edition", " pp", " 110–127", " https://doi", "org/10", "1017/CBO9780511910395", "008 Bereza, B", "G", ", MacHado, M", ", Ravindran, A", " V", ", Einarson, T", "R", ", 2012", " Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder", " Can", " J", " Psychiatry 57, 470–478", " https://doi", "org/10", "1177/070674371205700805 Busner, J", ", Targum, S", "D", ", 2007", " The clinical global impressions scale: applying a research tool in clinical practice", " Psychiatry (Edgmont)", " 4, 28–37", " Carneiro, A", "M", ", Fernandes, F", ", Moreno, R", "A", ", 2015", " Hamilton depression rating scale and montgomery-asberg depression rating scale in depressed and bipolar I patients: Psychometric properties in a Brazilian sample", " Health Qual", " Life Outcomes", " https://doi", "org/10", "1186/s12955-015-0235-3 Castillo, C", ", Macrini, L", ", Cheniaux, E", ", Landeira-Fernandez, J", ", 2010", " Psychometric properties DESENVOLVIMENTO 111 and latent structure of the portuguese version of the penn state worry questionnaire", " Span", " J", " Psychol", " 13, 431–443", " https://doi", "org/10", "1017/S113874160000398X Chalmers, J", "A", ", Heathers, J", "A", "J", ", Abbott, M", "J", ", Kemp, A", "H", ", Quintana, D", "S", ", 2016", " Worry is associated with robust reductions in heart rate variability: a transdiagnostic study of anxiety psychopathology", " BMC Psychol", " 4, 32", " https://doi", "org/10", "1186/s40359-016-0138-z Chalmers, J", "A", ", Quintana, D", "S", ", Abbott, M", "J", "-A", ", Kemp, A", "H", ", 2014", " Anxiety Disorders are Associated with Reduced Heart Rate Variability: A Meta-Analysis", " Front", " psychiatry 5, 80", " https://doi", "org/10", "3389/fpsyt", "2014", "00080 Choi, K", "W", ", Jang, E", "H", ", Kim, A", "Y", ", Fava, M", ", Mischoulon, D", ", Papakostas, G", "I", ", Kim, D", "J", ", Kim, K", ", Yu, H", "Y", ", Jeon, H", "J", ", 2019", " Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study", " J", " Affect", " Disord", " 246, 157–165", " https://doi", "org/https://doi", "org/10", "1016/j", "jad", "2018", "12", "048 Costa, M", " de A", ", Gonçalves, F", ", Tatton-Ramos, T", ", Fonseca, N", "K", ", Schwinn, J", ", Alves, S", ", Oliveira, F", "B", " de, Salum, G", "A", ", Manfro, G", "G", ", 2019", " A Three-Arm Randomized Clinical Trial Comparing the Efficacy of a Mindfulness-Based Intervention to an Active Control Group or Pharmacological Treatment for Adults with Generalized Anxiety Disorder", " Davies, C", "D", ", Niles, A", "N", ", Pittig, A", ", Arch, J", "J", ", Craske, M", "G", ", 2015", " Physiological and behavioral indices of emotion dysregulation as predictors of outcome from cognitive behavioral therapy and acceptance and commitment therapy for anxiety", " J", " Behav", " Ther", " Exp", " Psychiatry 46, 35–43", " https://doi", "org/10", "1016/j", "jbtep", "2014", "08", "002 de Abreu Costa, M", ", D’Alò de Oliveira, G", "S", ", Tatton-Ramos, T", ", Manfro, G", "G", ", Salum, G", "A", ", 2019", " Anxiety and Stress-Related Disorders and Mindfulness-Based Interventions: a Systematic Review and Multilevel Meta-analysis and Meta-Regression of Multiple Outcomes", " Mindfulness (N", " Y)", " 10, 996–1005", " https://doi", "org/10", "1007/s12671-018-1058- DESENVOLVIMENTO 112 1 Delgado, L", "C", ", Guerra, P", ", Perakakis, P", ", Vera, M", "N", ", del Paso, G", "R", ", Vila, J", ", 2010", " Treating chronic worry: Psychological and physiological effects of a training programme based on mindfulness", " Behav", " Res", " Ther", " 48, 873–882", " https://doi", "org/10", "1016/j", "brat", "2010", "05", "012 Ferreira-Garcia, R", ", Mochcovitch, M", ", do Cabo, M", "C", ", Nardi, A", "E", ", Freire, R", "C", ", 2017", " Predictors of Pharmacotherapy Response in Generalized Anxiety Disorder: A Systematic Review", " Harv", " Rev", " Psychiatry 25, 65–79", " https://doi", "org/10", "1097/HRP", "0000000000000127 [doi] Gallucci, M", ", 2019", " GAMLj: General analyses for linear models", " [ JAMOVI module]", " Hamilton, M", ", 1967", " Development of a Rating Scale for Primary Depressive Illness", " Br", " J", " Soc", " Clin", " Psychol", " 6, 278–296", " https://doi", "org/10", "1111/j", "2044-8260", "1967", "tb00530", "x Hamilton, M", ", 1959", " The assessment of anxiety states by rating", " Br", " J", " Med", " Psychol", " 32, 50–5", " Hofmann, S", "G", ", Sawyer, A", "T", ", Witt, A", "A", ", Oh, D", ", 2010", " The Effect of Mindfulness-Based Therapy on Anxiety and Depression: A Meta-Analytic Review", " J", " Consult", " Clin", " Psychol", " 78, 169–183", " https://doi", "org/10", "1037/a0018555 Hoge, E", "A", ", Bui, E", ", Marques, L", ", Metcalf, C", "A", ", Morris, L", "K", ", Robinaugh, D", "J", ", Worthington, J", "J", ", Pollack, M", "H", ", Simon, N", "M", ", 2013", " Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity", " J", " Clin", " Psychiatry 74, 786–792", " https://doi", "org/10", "4088/JCP", "12m08083 Hölzel, B", "K", ", Lazar, S", "W", ", Gard, T", ", Schuman-Olivier, Z", ", Vago, D", "R", ", Ott, U", ", 2011", " How does mindfulness meditation work? Proposing mechanisms of action from a conceptual and neural perspective", " Perspect", " Psychol", " Sci", " 6, 537–559", " https://doi", "org/10", "1177/1745691611419671 Kemp, A", "H", ", Brunoni, A", "R", ", Santos, I", "S", ", Nunes, M", "A", ", Dantas, E", "M", ", De Figueiredo, R", "C", ", Pereira, A", "C", ", Ribeiro, A", "L", "P", ", Mill, J", "G", ", Andreão, R", " V", ", Thayer, J", "F", ", Benseñor, I", "M", ", DESENVOLVIMENTO 113 Lotufo, P", "A", ", 2014", " Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: An ELSA-Brasil cohort baseline study", " Am", " J", " Psychiatry 171, 1328–1334", " https://doi", "org/10", "1176/appi", "ajp", "2014", "13121605 Khoury, B", ", Sharma, M", ", Rush, S", "E", ", Fournier, C", ", 2015", " Mindfulness-based stress reduction for healthy individuals: A meta-analysis", " J", " Psychosom", " Res", " 78, 519–528", " https://doi", "org/10", "1016/j", "jpsychores", "2015", "03", "009 Kircanski, K", ", Williams, L", "M", ", Gotlib, I", "H", ", 2019", " Heart rate variability as a biomarker of anxious depression response to antidepressant medication", " Depress", " Anxiety 36, 63–71", " https://doi", "org/10", "1002/da", "22843 Lu, G", ", Yang, F", ", Taylor, J", "A", ", Stein, J", "F", ", 2009", " A comparison of photoplethysmography and ECG recording to analyse heart rate variability in healthy subjects", " J", " Med", " Eng", " Technol", " 33, 634–641", " https://doi", "org/10", "3109/03091900903150998 Lueken, U", ", Zierhut, K", "C", ", Hahn, T", ", Straube, B", ", Kircher, T", ", Reif, A", ", Richter, J", ", Hamm, A", ", Wittchen, H", "-U", ", Domschke, K", ", 2016", " Neurobiological markers predicting treatment response in anxiety disorders: A systematic review and implications for clinical application", " Neurosci", " Biobehav", " Rev", " 66, 143–162", " https://doi", "org/https://doi", "org/10", "1016/j", "neubiorev", "2016", "04", "005 McNames, J", ", Aboy, M", ", 2006", " Reliability and accuracy of heart rate variability metrics versus ECG segment duration", " Med", " Biol", " Eng", " Comput", " 44, 747–756", " https://doi", "org/10", "1007/s11517-006-0097-2 Meyer, T", "J", ", Miller, M", "L", ", Metzger, R", "L", ", Borkovec, T", "D", ", 1990", " Development and validation of the penn state worry questionnaire", " Behav", " Res", " Ther", " https://doi", "org/10", "1016/0005-7967(90)90135-6 Pascoe, M", "C", ", Thompson, D", "R", ", Ski, C", "F", ", 2017", " Yoga, mindfulness-based stress reduction and stress-related physiological measures: A meta-analysis", " Psychoneuroendocrinology 86, DESENVOLVIMENTO 114 152–168", " https://doi", "org/10", "1016/j", "psyneuen", "2017", "08", "008 Quintana, D", "S", ", Alvares, G", "A", ", Heathers, J", "A", "J", ", 2016", " Guidelines for Reporting Articles on Psychiatry and Heart rate variability (GRAPH): recommendations to advance research communication", " Transl", " Psychiatry 6, e803", " https://doi", "org/10", "1038/tp", "2016", "73 Ruscio, A", "M", ", Hallion, L", "S", ", Lim, C", "C", "W", ", Aguilar-Gaxiola, S", ", Al-Hamzawi, A", ", Alonso, J", ", Andrade, L", "H", ", Borges, G", ", Bromet, E", "J", ", Bunting, B", ", De Almeida, J", "M", "C", ", Demyttenaere, K", ", Florescu, S", ", De Girolamo, G", ", Gureje, O", ", Haro, J", "M", ", He, Y", ", Hinkov, H", ", Hu, C", ", De Jonge, P", ", Karam, E", "G", ", Lee, S", ", Lepine, J", "P", ", Levinson, D", ", Mneimneh, Z", ", Navarro-Mateu, F", ", Posada-Villa, J", ", Slade, T", ", Stein, D", "J", ", Torres, Y", ", Uda, H", ", Wojtyniak, B", ", Kessler, R", "C", ", Chatterji, S", ", Scott, K", "M", ", 2017", " Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe", " JAMA Psychiatry 74, 465–475", " https://doi", "org/10", "1001/jamapsychiatry", "2017", "0056 Russell, T", ", 2011", " Body in mind training: mindful movement for severe and enduring mental illness", " Br", " J", " Wellbeing 2, 13–16", " https://doi", "org/10", "12968/bjow", "2011", "2", "4", "13 Schneider, R", "L", ", Arch, J", "J", ", Wolitzky-Taylor, K", "B", ", 2015", " The state of personalized treatment for anxiety disorders: A systematic review of treatment moderators", " Clin", " Psychol", " Rev", " 38, 39–54", " https://doi", "org/10", "1016/j", "cpr", "2015", "02", "004 Spitzer, R", "L", ", Kroenke, K", ", Williams, J", "B", "W", ", Löwe, B", ", 2006", " A brief measure for assessing generalized anxiety disorder: The GAD-7", " Arch", " Intern", " Med", " 166, 1092–1097", " https://doi", "org/10", "1001/archinte", "166", "10", "1092 Teper, R", ", Segal, Z", " V, Inzlicht, M", ", 2013", " Inside the Mindful Mind: How Mindfulness Enhances Emotion Regulation Through Improvements in Executive Control", " Curr", " Dir", " Psychol", " Sci", " 22, 449–454", " https://doi", "org/10", "1177/0963721413495869 The jamovi project, 2019", " jamovi", " Vest, A", "N", ", Da Poian, G", ", Li, Q", ", Liu, C", ", Nemati, S", ", Shah, A", "J", ", Clifford, G", "D", ", 2018", " An open DESENVOLVIMENTO", "3 CONCLUSÕES", "CONCLUSÕES 117 3 CONCLUSÕES A revisão de literatura buscando marcadores de mediação pôde efetivamente demonstrar que nenhuma variável clínica, dado demográfico ou biomarcador foi inequivocamente capaz de moderar a resposta clínica a qualquer tratamento farmacológico. O melhor potencial efeito de moderação encontrado, pela combinação do desenho do estudo com a força da hipótese a priori é a presença de sintomas depressivos subclínicos, que seria preditora de resposta ao tratamento farmacológico com antidepressivos em relação ao uso de benzodiazepínicos. Além disso, um grupo de variáveis de personalidade, genéticas e de neuroimagem, potencialmente relacionadas à regulação emocional parece prever uma pior resposta ao tratamento independentemente da intervenção utilizada. (FERREIRA-GARCIA et al., 2017). Estudos anteriores sugerem que elementos de regulação emocional seriam responsáveis por um aumento paradoxal em medidas de impulsividade em pacientes com TAG. No estudo 2, avaliamos a relação entre a prevalência de afetos negativos e impulsividade em pacientes com TAG e controles saudáveis. nossos resultados confirmaram nossa hipótese de que indivíduos com TAG relatam aumento da impulsividade em geral quando comparados a controles saudáveis. Especificamente, o efeito da faceta atencional do BIS foi atribuído à intensidade dos sintomas de preocupação. Também confirmamos a hipótese de que o afeto negativo se correlacionou com os escores de impulsividade apenas entre os pacientes, e que o efeito do diagnóstico de TAG na impulsividade foi completamente mediado pela afetividade negativa. Estes achados indicam que pacientes com TAG tender a ser mais impulsivos na presença de emoções negativas, confirmando indiretamente a relação já demonstrada na literatura entre urgência negativa e sintomas de TAG. APÊNDICE 2 121 disorders. Journal of Anxiety Disorders, v. 12, n. 3, p. 253–261, 1998. FERREIRA-GARCIA, R. et al. Predictors of Pharmacotherapy Response in Generalized Anxiety Disorder: A Systematic Review. Harvard review of psychiatry, v. 25, n. 2, p. 65–79, 2017. GAEBLER, M. et al. Heart rate variability and its neural correlates during emotional face processing in social anxiety disorder. Biological psychology, v. 94, n. 2, p. 319–330, 2013. GORENSTEIN, C.; ANDRADE, L. Validation of a Portuguese version of the Beck Depression Inventory and the State-Trait Anxiety Inventory in Brazilian subjects. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, v. 29, n. 4, p. 453–457, 1996. HOFFMAN, D. L.; DUKES, E. M.; WITTCHEN, H.-U. Human and economic burden of Generalized Anxiety Disorder. Depression and Anxiety, v. 25, p. 72–90, 2008. HUTZ, C. S. et al. O desenvolvimento de marcadores para a avaliação da personalidade no modelo dos cinco grandes fatores. Psicologia: Reflexão e Crítica, v. 11, p. 395–411, 1998. JOHN, O. P.; NAUMANN, L. P.; SOTO, C. J. Paradigm shift to the integrative big five trait taxonomy. Handbook of personality: Theory and research, v. 3, n. 2, p. 114–158, 2008. JOSEPH, B. O. et al. Anxiety and depressive disorders and the five-factor model of personality: A higher- and lower-order personality trait investigation in a community sample. Depression and Anxiety, v. 20, n. 2, p. 92–97, 2004. KESSLER, R. C.; KELLER, M. B.; WITTCHEN, H.-U. The Epidemiology of Generalized Anxiety Disorder. Psychiatric Clinics of North America, v. 24, n. 1, p. 19–39, 2001. LANG, P. J.; MCTEAGUE, L. M. The anxiety disorder spectrum: Fear imagery, physiological reactivity, and differential diagnosis. Anxiety, Stress, & Coping, v. 22, n. 1, p. 5–25, 2009. MENNIN, D. S. et al. Preliminary evidence for an emotion dysregulation model of generalized anxiety disorder. Behaviour Research and Therapy, v. 43, n. 10, p. 1281–1310, 2005. MOCHCOVITCH, M. D. et al. A systematic review of fMRI studies in generalized anxiety disorder: Evaluating its neural and cognitive basis. Journal of Affective Disorders, v. 167, p. 336–342, 2014. MOCHCOVITCH, M. D. Atualizações Do Tratamento Farmacológico Do Transtorno De Ansiedade Generalizada an Update on the Pharmacological Treatment of Generalized Anxiety Disorder. Revista Debates Em Psiquiatria, p. 14–18, 2015. MOELLER, F. G. et al. Psychiatric aspects of impulsivity. American Journal of Psychiatry, v. 158, n. 11, p. 1783–1793, 2001. MORENO, A. L. et al. Factor structure, reliability, and item parameters of the Brazilian-Portuguese version of the GAD-7 questionnaire. Temas em Psicologia, v. 24, n. 1, p. 367–376, 2016. APÊNDICE 2 122 ORMEL, J. et al. Neuroticism and common mental disorders: Meaning and utility of a complex relationship. Clinical Psychology Review, v. 33, n. 5, p. 686–697, 2013. PARK, G. et al. From the heart to the mind’s eye: cardiac vagal tone is related to visual perception of fearful faces at high spatial frequency. Biological psychology, v. 90, n. 2, p. 171–178, 2012. PAULUS, P. C.; CASTEGNETTI, G.; BACH, D. R. Modeling event-related heart period responses. Psychophysiology, v. 53, n. 6, p. 837–846, 2016. PAWLUK, E. J.; KOERNER, N. A preliminary investigation of impulsivity in generalized anxiety disorder. Personality and Individual Differences, v. 54, n. 6, p. 732–737, 2013. PEIRCE, J. W. Generating stimuli for neuroscience using PsychoPy. Frontiers in Neuroinformatics, v. 2, 2008. PIERÒ, A. Personality correlates of impulsivity in subjects with generalized anxiety disorders. Comprehensive Psychiatry, v. 51, n. 5, p. 538–545, 2010. SANDERSON, W. C.; BARLOW, D. H. A description of patients diagnosed with dsm-iii-r generalized anxiety disorder. Journal of Nervous and Mental Disease, v. 178, n. 9, p. 588–591, 1990. STEIN, D. J. [Ed]; HOLLANDER, E. [Ed]; ROTHBAUM, B. O. [Ed]. Textbook of anxiety disorders (2nd ed.). 2nd. ed. Arlington, VA: American Psychiatric Publishing, 2010. THAYER, J. F. et al. A meta-analysis of heart rate variability and neuroimaging studies: Implications for heart rate variability as a marker of stress and health. Neuroscience & Biobehavioral Reviews, v. 36, n. 2, p. 747–756, 2012.", "124 ANEXO 1 - TRANYLCYPROMINE PLUS AMITRIPTYLINE FOR ECT-RESISTANT DEPRESSION: A LONG-TERM STUDY Tranylcypromine plus amitriptyline for ECT-resistant depression: a long-term study Rafael Ferreira-Garcia, M", "D", " MSc, Rafael Christophe da Rocha Freire, M", "D", " Ph", "D", ", José Carlos Appolinário, M", "D", " Ph", "D", ", Michelle N", " Levitan, Ph", "D", ", Roseane Dorte Halkjær-Lassen, B", "S", "N", ", João Romildo Bueno, M", "D", " Ph", "D", ", Antonio E", " Nardi, M", "D", " Ph", "D", ", Laboratory of Panic & Respiration, Resistant Depression Outpatient Clinic Instituto de Psiquiatria - Universidade Federal do Rio de Janeiro Correspondence and reprints: Rafael Ferreira-Garcia Instituto de Psiquiatria - UFRJ Av", " Venceslau Brás, 71 – fundos", " Botafogo Rio de Janeiro –RJ CEP: 22290-140 Email: rafaelfg@ipub", "ufrj", "br FERREIRA-GARCIA, R", " et al", " Tranylcypromine Plus Amitriptyline for Electroconvulsive Therapy--Resistant Depression: A Long-Term Study", " Journal of clinical psychopharmacology, [s", " l", "], v", " 38, n", " 5, p", " 502–504, 2018", " 125 ABSTRACT Background: Few therapeutic options are available for patients with ECT-resistant major depressive disorder (ECT-r MDD), leaving a substantial proportion of this population beyond treatment possibilities", " The combination of monoamine oxidase inhibitors and tricyclic antidepressants could be a potential strategy for managing ECT-r MDD, and the specific association of amitriptyline and tranylcypromine may offer additional tolerability advantages", " Although promising, in our knowledge no studies have examined until now the effectiveness of this combination in ECT-r MDD", " Methods: We report a retrospective cohort of 31 patients with ECTr-MDD treated in an open-label fashion with the combination of amitriptyline and tranylcypromine", " Results: Overall, 80", "6% of the sample met response criteria at the end of the first 12-week of treatment", " Seventy-six percent (19 of 25) of the responders were followed for a mean of 9", "37±3", "86 years", " During this follow up period none of the patients had a recurring depressive episode", " The combination was well tolerated, while minor side effects were common, no severe or life-threatening events were reported throughout the study", " Conclusions: These findings indicate that the combination of tranylcypromine and amitriptyline is a potentially safe and effective candidate for future investigation in the treatment and long-term maintenance of ECTr- MDD", " 126 INTRODUCTION Treatment-resistant depression (TRD) is common, costly and extremely debilitating for the patients", " The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study indicates that even after four adequate drug trials, only about 67% of the patients respond adequately to treatment1", " Electroconvulsive therapy (ECT), currently the most effective strategy for managing TRD, and even the investigational drug ketamine, have shown remission rates of only 48% and 53%, respectively, in patients with a history of previous treatment failures2,3", " Nevertheless, very few options are available for patients with ECT-resistant major depressive disorder (ECT-r MDD), leaving a substantial proportion of this population beyond treatment possibilities", " The combined use of tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOI) was proposed as a reasonable alternative for patients suffering from major depressive disorder 4", " Indeed a few short-term studies have shown that the combination was safe and effective, but it was neither shown to be superior nor better tolerated when compared to either agent in monotherapy5", " Still, anecdotal evidence shows that the combination may be superior in patients with most severe symptoms, in TRD and patients with predominant atypical symptoms5", " Despite reports of severe fatal adverse reactions, and the potential increased risk for serotonin syndrome and hypertensive crisis, those were mostly associated specifically with imipramine, and to the addition of a TCA to an established course of an MAOI", " As a consequence, after a comprehensive review of all case reports and experimental studies, the combination was considered safe when both drugs are started simultaneously at low doses, and imipramine and clomipramine are avoided6", " Evidence for long-term safety and efficacy is limited but could be verified in a small number of patients for up to 3 years7", " 127 The combination of tranylcypromine and amitriptyline, specifically, may offer additional advantages over other drugs from the same classes", " Since amitriptyline has been shown to inhibit tyramine uptake, and decrease tyramine pressure response in patients taking MAOI, in a small experimental study, it was suggested that this combination could lower the probability of hypertension caused by the consumption of tyramine-rich food8", " Also, at least one retrospective case series indicated a relative superiority of the combination of tranylcypromine and amitriptyline over other tricyclics 9", " Although promising, to our knowledge, no previous study has examined the efficacy and safety of the combination of tranylcypromine and amitriptyline in patients with ECT-resistant depression", " We report a retrospective cohort of patients with ECTr-MDD treated in an on open-label fashion with the combination of amitriptyline and tranylcypromine", " 128 METHODS This is a long-term retrospective follow-up of patients treated with tranylcypromine plus amitriptyline", " We included data extracted from clinical charts of patients with an initial diagnosis of major depressive disorder according to DSM-III-R, or DSM IV-TR, a minimum score of 25 on the Portuguese version of the 17-item Hamilton Depression Scale (HAMD)10, and documented resistance to at least (1) four adequate antidepressant pharmacological trials, including one trial of a TCA and one trial of tranylcypromine; and (2) one complete course of at least seven bilateral ECT treatments", " Adequacy of previous pharmacotherapy was defined by the use of an effective dose of an antidepressant, including potentiation strategies, for at least six weeks", " All patients received treatment following standard dosing and follow-up protocol", " After clinical examination and clearance, they were started on open-label 10mg/day tranylcypromine and 25mg/day amitriptyline and which were increased simultaneously to a maximum dose of 80mg and 150mg/day respectively throughout four weeks", " All patients were assessed at week 2, 4, 8 and 12 using both the HAMD and Clinical Global Impression (CGI) severity and were evaluated for side effects by the attending clinician", " Treatment response was defined as a 50% reduction in HAMD scores at 12 weeks", " Treatment was discontinued for patients that did not respond at this time point", " Treatment responders at 12 weeks were maintained in long-term follow up with the same drug regimen, with maximum tolerated doses", " Data on long-term depressive symptoms were extracted from each patient’s last visit", " Statistical analysis was performed using the JASP statistical software 11", " We assessed efficacy in the short-term (first 12 weeks) using repeated measures ANOVA to test for effects of time on HAMD and CGI scores and used t-tests when simple comparisons of means were required", " For the 12-week open study, we used the last observation carried forward method of 129 imputation for missing data from dropouts", " The statistical significance threshold was set at p = 0", "05", " This study was approved by the local ethics committee", "", "130 RESULTS: We included clinical charts of 31 patients, 19 females and 12 males that met inclusion criteria to our study", " Mean age was 44", "74±10", "24 years, and mean time from the index diagnosis was 15", "0 ±8", "51 years", " Baseline mean HAMD was 32", "57±3", "64, which corresponded to CGI scores of 7 (n=9) and 6 (n=22)", " Twenty-five patients (80", "6%) met response criteria at the end of the first 12-week trial and were enrolled in long-term follow-up", " There was a significant effect of time on HAMD scores (F = 155", "30, p<0", "001, Greenhouse-Geisser correction) on weeks 2, 4, 8 and 12, as shown by percent improvement on HAMD scores, which decreased progressively for the 12 weeks (figure 1)", " Mean HAMD scores were significantly lower at 12 weeks (32", "51±3", "64 vs", " 11", "80±7", "79, p < 0", "001), as were CGI scores (6", "29±0", "46 vs", " 2", "39±1", "52, p<0", "001)", " 23 patients (74", "2%) had CGIs of 1 or 2 at the end of 12 weeks", " 6 patients dropped out of initial treatment, 3 (9", "7%) of whom opted out of treatment for insufficient clinical response and 3 (9", "7%) for intolerable side effects, specifically 1 (3", "2%) for sedation, 1 (3", "2%) for constipation and 1 (3", "2%) for postural hypotension", " Long-term data could be recovered for 19 of 25 (76%) patients that responded to treatment in the first 12 weeks", " Mean follow up time was 9", "37±3", "86 years (range = 4 to16 years)", " None of the patients had a recurring depressive episode during follow up, only occasionally minor symptoms, and HAMD scores were not significantly different from 12 weeks to the last long-term measurement (8", "16±2", "24 vs", " 9", "36±3", "86, p=0", "32)", " As expected, side effects were common, and most patients reported more than one new onset symptom after treatment was started (table 1)", " Nonetheless, no severe or life-threatening side effects were reported throughout the study", " Of note, no cases of serotonin syndrome, new-onset hypertension or hypertensive crises were diagnosed neither during initial treatment nor in the long-term follow-up phase", " 131 DISCUSSION Very few options are currently available for treating patients with major depressive disorder who do not respond to an adequate course of ECT", " Therefore, any new treatment that shows promising results for this underserved population should be the object of intensive investigation", " The ideal candidate would be a pharmacological treatment that is shown to be effective, safe, inexpensive, and could also be used as long-term prophylaxis against recurring depressive symptoms", " In this retrospective study, we report the potential efficacy and long-term safety of tranylcypromine and amitriptyline in combination for patients with ECT-refractory major depressive disorder", " The patients in this cohort achieved a surprisingly high response rate (80,6%), for a treatment resistant-population", " That was, nevertheless, similar to previous reports", " In a retrospective chart review, from 94 patients suffering from treatment-resistant depression treated with tranylcypromine and various TCA in combination, 68% had “no” or “very little depressive symptomatology” at the end of the trial9", " Furthermore, from the 37 patients treated with tranylcypromine and amitriptyline, 78% responded, closely matching our results", " A 74% response rate was also reported by Razani et al", " 12 for patients with similar pre-treatment severity scores, but no reported resistance, in a prospective randomized trial", " A different MAOI (isocarboxazid) was used in a prospective open trial in which a 68% response rate was observed for patients with treatment-resistant depression7", " Although intuitively, one might expect lower response rates in patients with for ECT-resistant depression, our findings suggest that the combination of tranylcypromine and amitriptyline can be effective for that group of patients, with response rates that should not prove to be too inferior to those observed in non-ECT-resistant depression", " Our results also indicate that long-term treatment with the combination of tranylcypromine and amitriptyline is likely safe, after initial treatment response, and severe side 132 effects should not be expected on the patients in long-term follow-up", " Those findings are in line with the findings of a smaller 3-year follow-up study of 6 patients using isocarboxazid associated with amitriptyline, reported by Berlanga and Ortega-Soto7", " We extended those findings with a larger sample and for an average ten years follow-up period, confirming, thus, the feasibility of the combination as potential long-term prophylaxis for a selected group of patients", " We acknowledge the limitations of our study", " Although we could recover initial response scores from standardized measurements, and treatment was offered in a standardized form, our study is still a retrospective cohort, and we, therefore, cannot make strong claims on the efficacy of the offered intervention", " Also, although our sample had a relatively low attrition rate both in the initial treatment phase and in the follow-up phase, we cannot exclude some selection bias, so it is possible, although unlikely, that severe side effects and recurrences were found exclusively on the dropout subjects", " On the other hand, for efficacy measures, the potential bias introduced by dropouts was minimized by using LOCF as the imputation method", " Our findings, on the whole, indicate that the combination of tranylcypromine and amitriptyline is a potentially safe and effective candidate for the long-term treatment of ECT-refractory major depressive disorder", " While the authors do not believe there is nearly enough data to support the adoption of this combination outside specialized academic treatment settings, the confirmation of this findings would add a new treatment option to patients for whom we can offer very few alternatives", " This study nevertheless supports the elaboration of future experimental trials specifically designed to test the effectiveness of the combination of tranylcypromine and amitriptyline against placebo on ECT-refractory patients", " 133 REFERENCES: 1", " Warden D, Rush AJ, Trivedi MH, et al", " The STAR*D project results: A comprehensive review of findings", " Curr Psychiatry Rep", " 2007;9:449-459", " 2", " Murrough JW, Iosifescu D V", ", Chang LC, et al", " Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial", " Am J Psychiatry", " 2013;170:1134-1142", " 3", " Heijnen WT, Birkenhäger TK, Wierdsma AI, et al", " Antidepressant pharmacotherapy failure and response to subsequent electroconvulsive therapy: A meta-analysis", " J Clin Psychopharmacol", " 2010;30:616-619", " 4", " Spiker DG, Pugh DD", " Combining Tricyclic and Monoamine Oxidase Inhibitor Antidepressants", " Arch Gen Psychiatry", " 1976;33:828-830", " 5", " Thomas SJ, Shin M, McInnis MG, et al", " Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: Strategies for the management of treatment-resistant depression", " Pharmacotherapy", " 2015;35:433-449", " 6", " White K, Simpson G", " Combined MAOI-tricyclic antidepressant treatment: a reevaluation", " J Clin Psychopharmacol", " 1981;1:264-282", " 7", " Berlanga C, Ortega-Soto HA", " A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination", " J Affect Disord", " 1995;34:187-192", " 8", " Pare CMB, Hallstrom C, Kline N, et al", " Will Amitriptyline Prevent the “Cheese” Reaction of Monoamine-Oxidase Inhibitors? Lancet", " 1982;320:183-186", " 9", " Schmauss M, Kapfhammer HP, Meyr P, et al", " Combined MAO-inhibitor and tri- (tetra) cyclic antidepressant treatment in therapy resistant depression", " Prog Neuropsychopharmacol Biol Psychiatry", " 1988;12:523-532", " 10", " Freire MÁ, Figueiredo VLM de, Gomide A, et al", " Escala hamilton: Estudo das 134 características psicométricas em uma amostra do sul do Brasil", " J Bras Psiquiatr", " 2014;63:281-289", " 11", " JASP Team", " JASP (Version 0", "8", "6", "0)", " Retrieved from http//jasp-stats", "org", " 2018", " 12", " Razani J, White KL, White J, et al", " The Safety and Efficacy of Combined Amitriptyline and Tranylcypromine Antidepressant Treatment: A Controlled Trial", " Arch Gen Psychiatry", " 1983;40:657-661", " Fig 1", " Mean percent improvement on HAMD from baseline to week 12", " (Week 2 – 17", "2 ± 10", "2, Week 4 - 35", "0 ± 14", "3, Week 8 – 51", "0 ± 17", "4, Week 12 – 63", "7 ± 22", "2) Error bars represent SD values", "", "136 Symptom N (%) Dry mouth 28 (90,3) Nausea 26 (83,9) Orthostatic hypotension 25 (80,6) Libido (decrease) 22 (71,0) Somnolence 18 (58,1) Dizziness 10 (32,3) Constipation 10 (32,3) Delayed ejaculation 8 (66,6) Insomnia 5 (16,1) Headache 5 (16,1) Table 1. Reported side effects of the amitriptyline/tranylcypromine combinat"]}